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Abstract 
 
Cardiac arrhythmias are a major cause of morbidity and mortality in the industrialized world. Among their treatment 
regimens one can find the calcium channel antagonists (CCAs), the class IV agents. In the cardiovascular system L- 
and T-type calcium channels are found on vascular smooth muscle cells and cardiac myocytes with well defined 
physiological roles. Inhibition of calcium channels by CCAs has widely been used in clinical practice for several 
decades. Cardiovascular disorders are one of the many fields of medicine in which CCAs are used for various 
reasons and conditions. The three main indications of them are hypertension, angina and various cardiac arrhythmias. 
The most important classes of CCAs are dihydropyridines, phenylalkylamines and benzothiazepines but some newer 
compounds do not fall into any of these major classes. Dihydropyridines are not used in the antiarrhythmic therapy 
but are good vasodilators and antianginal agents. In contrast, phenylalkylamines and benzothiazepines exert cardiac 
actions in vivo and therefore these are one choice of antiarrhythmic drugs. This review focuses on 
phenylalkylamines, benzothiazepines and on new drugs with potential antiarrhythmic action in the heart as well as 
the mechanisms how calcium channels antagonism can lead to an antiarrhythmic action. 
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1. Introduction 
 
Cardiac arrhythmias are a large group of conditions in which the normal, precisely timed electrical activity 
of the heart is perturbed. This group includes many, greatly diverse disorders from the reduction of electrical activity 
in sick sinus syndrome or various forms of bradycardia through the single supraventricular or ventricular 
extrasystoles to the life-threatening tachyarrhythmias like ventricular fibrillation (VF). The most common form of 
arrhythmias is atrial fibrillation (AF) which does not usually lead to sudden cardiac death but its complications can 
be severe [1]. Sudden cardiac death is often a consequence of VF which occurs mostly on the ground of ischemic 
heart disease [2] and is a major cause of mortality in Europe and the USA [3]. In the management of cardiac 
arrhythmias pharmacological treatment is used beside electrical interventions as catheter ablation. In the former the 
arsenal of drugs keeps continuously increasing but according to the probably most commonly used classification they 
belong to one of the five major groups of the Vaughan Williams classification [4]. Drugs that reduce the ionic 
current flowing through calcium channels, the calcium channel antagonists (CCAs) fall into class IV of this 
classification. CCAs are being used in clinical practice for a long time now and not only in cardiovascular disorders. 
The three main indications of CCAs are hypertension, angina and various cardiac arrhythmias in cardiology. The 
most important classes of CCAs are dihydropyridines, phenylalkylamines and benzothiazepines but some newer 
compounds do not fall into any of these major classes. 
Calcium channels are found on almost every cell in the human body and classified to various types 
including L-, N-, P/Q-, R-, and T-types. These channel proteins have several subunits and the α1 subunit is the pore 
forming one among them, whereas others (α2, β, γ, and δ) also have well defined roles [5]. In vascular smooth 
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muscle cells (SMCs), the L-type channels (Cav1.2) whereas in cardiac cells in adulthood, both L- (Cav1.2 and to a 
lesser extent Cav1.3) and T-types (Cav3.1 and Cav3.2) are found; the latter ones present only in nodal tissues with 
pacemaker activity. Their function is essential in the maintenance of vascular tone and contraction in arterioles, for 
the impulse generation and propagation in nodal tissues and last but not the least, for contraction of working 
myocardium [5]. This review focuses on the evidence of antiarrhythmic actions of some CCAs, the potential 
mechanisms leading to this beneficial effect, the comparison of actions of various CCAs and a structure-activity 
relationship of the presented CCAs. 
 
2. Dihydropyridines (a large class of CCAs with no antiarrhythmic activity) 
 
Dihydropyridines (Fig. 1.) are only mentioned very briefly for the sake of completeness as these are one of 
the three major classes of organic CCAs. Dihydropyridines are not used in the antiarrhythmic therapy due to their 
high vascular over cardiac selectivity [6]-[7]. Mechanisms of this vascular selectivity include at least two factors. 
One is the well known voltage- and use-dependent L-type channel inhibition [10] which taken together with the fact 
that SMCs are more depolarized compared to myocardium results in a higher inhibition of calcium channels in 
SMCs. Another mechanism is the different isoform of α1 in SMCs and myocardium and the observation that the 
smooth muscle isoform expressed in CHO cells is more sensitive to inhibition by neutral dihydropyridines but not by 
verapamil [9]. 
Dihydropyridines are good vasodilators and often used in combination with other hypertensive agents [11]. 
Dihydropyridines are also useful as antianginal agents [12]. The short acting dihydropyridines are more likely to 
cause sudden vasodilatation than those with longer onset and duration of action and therefore short acting ones more 
likely evoke stimulation of the sympathetic nerves leading to reflex tachycardia [13], [14]. This action is not 
beneficial especially in hypertensive patients with angina and ischemia where the further increase in myocardial 
oxygen requirement should be avoided. 
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FIG. 1. Chemical structure of dihydropyridines. The first and best known one is the circled nifedipine. Those 
compounds marked with asterisks are the long acting ones. 
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3. The calcium channel inhibitory actions of some CCAs 
 
3.1. Actions on the L-type calcium channels 
CCAs usually exert a use-dependent inhibition on L-type Ca2+ channels (ICa,L) as it was described with 
verapamil in rat ventricular myocytes [15]. Similar observation was made with D600 (gallopamil) in rabbit and feline 
ventricular muscle [16], with tiapamil (RO 11-1781) in guinea-pig urinary bladder SMCs [17] and with diltiazem in 
human atrial and ventricular myocardium [18] as well as in rat aorta SMCs [19]. Not only use-, but voltage-
dependent inhibition was observed with tiapamil in guinea-pig urinary bladder SMCs [17] and diltiazem in human 
atrial and ventricular myocardium [18]. It was suggested that verapamil blocked more effectively the inactivated 
channels [15] and also that it preferentially acted on the open state of the channels [19] similarly to diltiazem. The 
effectivity of phenylalkylamine and benzothiazepine type CCAs on L-type calcium current (ICa,L) is compared in 
Tables 1 and 2. 
 
TABLE 1. The half-inhibitory concentrations (IC50) of phenylalkylamine CCAs (Fig. 2.) on ICa,L. 
 
DRUG IC50 value Holding potential Species/preparation Reference 
less than 100 nM -40 mV guinea-pig/ventricular 
myocytes 
[20] 
246 nM -50 mV rat/ventricular myocytes [21] 
900 nM -80 mV, followed 
by a 20 ms long 
-40 mV prepulse 
rat/ventricular myocytes [15] 
Verapamil 
600 nM -60 mV rat/aorta SMCs [19] 
1 µM -40 mV guinea-pig/ventricular cells [20] 
less than 1 µM -60 mV frog/atrial cells [22] 
D600 (gallopamil) 
less than 1 µM -60 mV cat/ventricular muscle [23] 
Tiapamil 
(RO 11-1781) 
around 1 and 
20 µM 
-45 and -65 mV guinea-pig/urinary bladder 
SMCs 
[17] 
 
 6 
TABLE 2. Benzothiazepine CCA (Fig. 3.) effects on ICa,L and contractions. 
 
Molecules with structures different from both phenylalkylamines and benzothiazepines (and also from 
dihydropyridines) can also inhibit ICa,L. Some of these (Fig. 4.) can show some structural similarity to one (or more) 
of the major groups of CCAs but some are completely different without any sign of structural similarity (Fig. 5.). 
The IC50 values of these substances are summarized in Table 3. On top of the concentration-dependent inhibition of 
ICa,L many of these drugs had additional effects on the kinetics of ICa,L. 
Semotiadil shifted the voltage-dependent inactivation curve to the left and accelerated the decay of the current in 
concentrations higher than 1 µM. At 1 µM it also slowed the recovery from inactivation. Long-lasting inhibition of 
ICa,L after removal of semotiadil may be due to tight binding of semotiadil on the channel through a hydrophobic site 
[32]. Levosemotiadil also shifted the steady-state inactivation curve to more negative potentials [33] just as it was 
observed with fantofarone [34] as well as with bepridil [35]. Fantofarone blocked ICa,L in a voltage-dependent 
manner in rat ventricular myocytes, and evoked both tonic and use-dependent blockade of ICa,L [34]. The voltage-
dependent inhibition of ICa,L was detected with SR33805 [36] and bepridil [37]. Inhibition of ICa,L by 5 µM AH-1058 
had both tonic (25 % reduction) and use-dependent component (further 60% reduction) [38]. Bepridil slowed the 
recovery from inactivation of ICa,L [35]. 
 
DRUG IC50 value or percentage reduction / 
holding potential 
Species/preparation Reference 
512 nM in reduction of ICa,L / -50 mV rat/ventricular myocytes [21] 
630 nM in reduction of ICa,L / -50 mV guinea-pig/ventricular cells [24] 
500 nM in reduction of ICa,L / -40 mV ferret/right ventricular 
papillary muscles 
[25] 
3 µM in reduction of ICa,L / -60 mV rat/aorta SMCs [19] 
300 µM in reduction of IBa / -60 mV rabbit/mesenteric artery SMCs [26] 
694 nM in reduction of tension human/coronary artery [27] 
277 nM in reduction of tension rabbit/aorta [28] 
25 % reduction of contractile force by 
10 µM 
rabbit/atrial muscle [29] 
25 % reduction of calcium-evoked 
contraction by 1 µM 
sheep/cerebral artery [29] 
25 % reduction of calcium-evoked 
contraction by 80 nM 
sheep/depolarized coronary 
artery ring 
[30] 
120 nM on reduction of potassium-induced 
contraction 
rat/thoracic aorta [31] 
Diltiazem 
over 10 µM on vasodilatation of 
phenylephrine precontracted vessels 
rat/thoracic aorta [31] 
30 µM in reduction of IBa / -60 mV rabbit/mesenteric artery SMCs [26] 
221 nM in reduction of tension human/coronary artery [27] 
Clentiazem 
(TA-3090) 
61 nM in reduction of tension rabbit/aorta [28] 
25 % reduction of contractile force by 
10 µM 
rabbit/atrial muscle [29] 
25 % reduction of calcium-evoked 
contraction by 1 µM 
sheep/cerebral artery [29] 
Siratiazem 
(LR-A113) 
25 % reduction of calcium-evoked 
contraction by 130 nM 
sheep/depolarized coronary 
artery ring 
[30] 
190 nM on reduction of potassium-induced 
contraction 
rat/thoracic aorta [31] S-2150 
29 nM on vasodilatation of phenylephrine 
precontracted vessels 
rat/thoracic aorta [31] 
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TABLE 3. The inhibitory potency of other CCAs (Fig. 4 and 5.) on ICa,L. 
 
DRUG IC50 value / holding 
potential 
Species/preparation Reference 
between 10 and 100 µM /  
-80 mV followed by a 50 
ms long -40 mV prepulse 
guinea-pig/ventricular cells [39] Semotiadil (SD-3211) 
84, 900 and 2000 nM /  
-60, -80 and -100 mV 
rabbit/portal vein SMCs [32] 
Levosemotiadil (SD-3212) 1.3 µM / -40 mV guinea-pig/atrial cells [33] 
22 nM and 9 µM / 
-50 and -80 mV 
rat/ventricular myocytes [34] Fantofarone (SR 33557) 
1.4 and 150 nM / 
-40 and -80 mV 
mouse/cardiac cells in primary 
culture 
[36] 
4.1 and 33 nM / 
-40 and -80 mV 
mouse/cardiac cells in primary 
culture 
[36] SR 33805 
24 nM / -80 mV rat/ventricular myocytes [40] 
BRL-32872 2.8 µM / -50 mV guinea-pig/ventricular cells [41] 
KT-362 28.6 % reduction in 7 µM / 
-40 mV 
dog/Purkinje cells [42] 
Monatepil (AJ-2615) 18.7 nM / -40 mV guinea-pig/ventricular cells [43] 
2.6 µM / -70 mV followed 
by a -40 mV prepulse 
guinea-pig/ventricular cells [44] 
0.5 µM / -50 mV guinea-pig/ventricular cells [35] 
Bepridil 
1.55 µM / -40 mV guinea-pig/atrial cells [33] 
AH-1058 0.32 and 4.91 µM /  
-40 and -80 mV 
guinea-pig/ventricular cells [45] 
 
3.2. T-type calcium channel inhibition of CCAs 
Mibefradil (Fig. 5.) is usually regarded as a selective inhibitor of the T-type calcium channels (ICa,T). Later 
it turned out that it is not entirely specific as ICa,L is also reduced by mibefradil. Martin et al. review the literature and 
list these actions of the drug. Usually the inhibitory effect of mibefradil on native ICa,T is more potent compared to 
that on native ICa,L by 13-70, 17 and 3 times in vascular smooth muscle, atrial myocytes and human myoblasts, 
respectively [46]. Mibefradil blocked 2-3 times more potently ICa,T compared to that of ICa,L in guinea-pig ventricular 
myocytes [47]-[49] but 30 times more potently in rat ventricular cells [50]. In contrast, in rabbit sinoatrial (SA) node 
cells 1 µM mibefradil reduced ICa,T less than ICa,L (by 55 and 64 %, respectively) [51]. Regarding the mibefradil 
inhibition of ICa,T and ICa,L some found that only the latter one was blocked strongly in a voltage- and use-dependent 
manner [49]. In contrast, in rat ventricular cells both ICa,T and ICa,L was reduced by mibefradil in a voltage- and use-
dependent manner [50]. In canine Purkinje fibers mibefradil blocked calcium currents and in the presence of 1 µM 
mibefradil the T/L current ratio was reduced. The steady-state activation half-potentials were shifted to the left by 40 
and 10 mV for ICa,L and ICa,T, respectively [52]. Compared to other CCAs, mibefradil was less potent than verapamil 
in inhibiting calcium current in isolated guinea-pig myocytes [53]. The inhibitory action of mibefradil on ICa,T was 
approximately twice more potent compared to that of ICa,L [47]. 
Not only mibefradil blocks ICa,L in addition to ICa,T but other CCAs also reduce ICa,T on top of the ICa,L. Verapamil 
block of ICa,T was observed in guinea-pig ventricular cells (10 % reduction by 1 µM, same extent as in ICa,L) [47] and 
in rat aorta SMCs (IC50 of 30 µM) which showed no use-dependence [19]. In contrast, stably expressed human 
Cav3.1 T-type channels in human embryonic kidney (HEK) cells were blocked by verapamil in a use- and voltage-
dependent manner with an IC50 of 21.4 µM and the drug significantly slowed the recovery from inactivation. It was 
suggested that verapamil achieves its inhibitory effect via occlusion of the channel pore associated with an 
open/inactivated conformation of the channel [54]. 
10 µM diltiazem (which reduced ICa,L by 18 %) had no action on T-type calcium channels in guinea-pig ventricular 
myocytes [47] but in rat aorta SMCs it reduced ICa,T with an IC50 of 30 µM, ten times less potently than ICa,L. 
Diltiazem, similarly to verapamil, preferentially acted on the open state of the L-type calcium channel and on the 
resting and inactivated states of the T-type calcium channel [19]. 
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Bepridil reduced ICa,T in a voltage-independent manner in guinea-pig atrial myocytes; therefore at normal diastolic 
potentials (~-90 mV) it actually reduced ICa,T more potently than ICa,L [37]. In contrast, block of Cav3.2 channels 
(underlying ICa,T) in HEK cells was voltage-dependent but frequency-independent. IC50 yielded 0.4 µM at -70 mV 
holding potential (26 times lower than at -100 mV). Bepridil (10 µM) shifted both steady-state activation and 
inactivation to more negative potentials but did not affect the recovery kinetics [55]. 
Within the reviewed CCAs there are some without major inhibitory action on ICa,T like D600. 1 µM D600 (causing 
complete inhibition of ICa,L) did not reduce ICa,T in rabbit SA cells [56]. In primary cultured murine cardiac cells ICa,T 
was not reduced by either 100 nM fantofarone or 100 nM SR 33805 [36]. 
 
4. Structure-activity relationship of CCAs 
 
4.1. Benzothiazepines 
Benzothiazepines are one of the three major classes of CCAs which exert a functional state-dependent 
inhibition of the L-type calcium channel (inactivated>open>closed) [57]. High affinity binding of benzothiazepines 
requires Ca2+ bound to the channel [57]. On the contrary, increased concentration of Ca2+ antagonize diltiazem block 
of the channels in both heart [58] and smooth muscle [59]. The extracellular application of benzothiazepines 
effectively blocks the L-type Ca2+ channel but the intracellular application does not secure the inhibitory effect. This 
led to the conclusion that benzothiazepine block is mediated from the extracellular side of the channel pore [60], 
[61]. These findings were found plausible by Monte Carlo simulation [57]. The pathway leading to the binding site 
of the inner pore of the channel was found to be wide enough for the molecule to “penetrate” [62]. Despite these 
concurrent results, the quaternary ammonium derivative of diltiazem was found to be able to inhibit the L-type 
channels from the intracellular side [63]. 
The presence of Ca2+ is an important factor in ligand-channel binding. The Ca2+ in the selectivity filter was 
found to bind not only to the carbonyl groups of benzothiazepine but also to the glutamates of the selectivity filter 
[57]. In the absence of calcium ions the amino group of benzothiazepine molecule interacts with the previously 
mentioned glutamates directly [57]. The interaction of the aromatic rings with the Y4i11, F3i22 and F3p49 residues 
is also important [57]. Substitution in position 3 of the 7 member heteroatomic ring has only moderate effect on 
benzothiazepine binding. However, this side group should be preferably hydrophobic to increase the inhibitory 
action [64]. The length of the alkyl chain between the nitrogen atoms does not influence the binding of the 
benzothiazepine to the channel [57]. Benzothiazepine interaction with a closed calcium channel was destabilized due 
to loss of contact sites at the C terminal of the inner helices [57]. Systematic point mutation of the amino acids in 
domains IIIS6 and IVS6 highlighted the essential residues for the diltiazem block, for instance I1150, I1156 and 
M1160 in IIIS6 as well as I1460 and M1464 in IVS6 [65]. 
The Ca2+ channel inhibitory and hypotensive effects of the derivatives of diltiazem were also investigated in 
several articles. Clentiazem (8-chloro-diltiazem) was also found to be able to reduce peripheral arterial resistance 
[66]. Assumingly, this effect mediated by the same manner as L-type Ca2+ channel inhibition by diltiazem. In S-2150 
the dimethyl amino group was replaced by a complex (2-methoxyphenyl)-1-piperazinyl substituent. The nitrogen 
atoms in the piperazinyl ring may have the same effect as the amine nitrogen in clentiazem. The connecting ethylene 
chain was increased to propylene group, but this does not seem to have an effect on calcium channel inhibition (see 
above) [57]. The additional methoxy group probably plays a role in calcium chelating just like in the 
phenylalkylamines [67]. This molecule found to be less cardio-depressive than diltiazem [68] but its hypotensive 
effect is 4-7 times more potent than that of diltiazem [31]. This different vascular over cardiac selectivity may come 
from the wide spectra of the effects of benzothiazepine and derivatives, which are not just restricted to the L-type 
Ca2+ channel inhibition [69]. Siratiazem hardly differs from diltiazem as just one of the methyl groups was 
substituted to isopropyl group. This modification might mimic one of the essential parts of verapamil binding 
properties [70]. Semotiadil (SD-3211) and its S-enantiomer sesamodil (levosemotiadil, SD-3212) can both inhibit 
potassium depolarization-induced cytosolic Ca2+ increase in rat aorta [71]. We classified these two molecules as 
benzothiazepine-like compounds despite the smaller (only six member) heteroatomic ring containing the sulphur and 
nitrogen atoms. This might alter the Baeyer tension of the ring. These compounds also contain motifs similar to 
phenylalkylamines such as tertiary amine nitrogen and methoxy group attached to an aryl ring [67]. 
 
4.2. Phenylalkylamines 
Articles described the mechanisms of verapamil binding to a synthetic channel peptide (SCP), which has 
authentic functional properties as the L-type Ca2+ channel [67]-[70]. Verapamil binds snugly to the pore of the 
channel in a folded conformation. Based on the Monte Carlo method with energy minimization, they showed that 
two important parts of the verapamil take part in the Ca2+ channel blocking action. Firstly the dimethoxy-phenyl 
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groups are bound with two Ca2+ ions coordinated to the acidic residues of the channel pore [67]. That is how a 
ternary complex is formed involving the channel, the ions and the antagonist. The second is the isopropyl group of 
verapamil which interacts with the four Ile residues of the channel constituting the putative gate of the SCP [67]. 
Other authors claim that isopropyl group of devapamil reaches the T2p48 and F3p49 residues [72]. Another study 
showed that verapamil, similarly to D600, blocked L-type Ca2+ channel only if applied from the extracellular side 
[73]. In contrast, others found that both D600 and verapamil are able to reduce action potential duration (APD) and 
plateau potential of cardiac AP dose-dependently, regardless of the intra- or extracellular application in isolated 
guinea-pig ventricular myocytes [74]. D600 (often mentioned as gallopamil) only differs from verapamil by an 
addition of a methoxy group to that aryl ring which is located closer to the nitrile group. This may increase the Ca2+ 
chelating effect of the molecule, or the number of available sites for hydrogen bond formation [75]. Anipamil was 
designed to be less hydrophilic and binding studies showed that anipamil, although binds tightly to cardiac 
membranes, its binding to the D888 (desmethoxyverapamil) binding sites is less potent compared to verapamil [76]. 
The number of methoxy groups was halved on each aromatic ring, and the isopropyl group was substituted with a 
longer, linear dodecyl group. These changes resulted in the decrease of the inhibitory potency, but prolonged effects 
[76]. Tiapamil misses the isopropyl [70] and the nitrile group [77] existing in both verapamil and D600. These 
functional groups considered as important channel-ligand interaction sites [72]. In spite of these preconceptions, two 
oxygen atoms from the bulky saturated six-membered ring interact with the calcium ion in the pore [72]. Nadler and 
his coworkers thoroughly investigated the electrophysiological effects of BRL 32872 and its synthetic derivatives. 
These compounds blocked the ion channels responsible for the rapid component of the delayed rectifier potassium 
current (IKr) on top of L-type calcium channels [78]. The authors stated that the hydrogen bond formation, the 
nitrogen substituted with aliphatic alkyl chains, but not the quaternization of nitrogen and the aromatic substitution 
are crucial for the inhibitory effect. The too long aliphatic nitrogen substitution decreases the activity of the 
molecule, which also supports the result of Dillon and his coworkers [76]. Fantofarone and SR 33805 show strong 
structural similarities to each other such as dimethoxy substituted aryl rings, nitrogen substituted with three aliphatic 
alkyl chain, isopropyl and sulfonyl groups. The role of these functional groups (except the sulphonyl group) is 
presumably the same as mentioned earlier in this chapter [67],[70],[78]. The sulfonyl group might participate in 
chelating the Ca2+ similarly to that mentioned with tiapamil [72]. SR 33805 was shown to inhibit competitively 
[3H]fantofarone, while allosterically [3H](+)-PN200-110, [3H](-)-D888 and cis-(+)-[3H]diltiazem binding to cardiac 
sarcolemmal membranes. This suggests that, just as fantofarone, it binds to a site different from that of 
dihydropyridines, phenylalkylamines and benzothiazepines [79]. 
 
4.3. Other compounds 
The structure-activity relationship of the following compounds is based on the findings described in the 
previous two sections. 
KT-362 shows motifs from both phenylalkylamine and benzothiazepine structure elements. It “inherited” 
the heteroatomic ring of the benzothiazepines, however, that ring is more substituted in diltiazem. It also contains 
methoxy groups attached to an aryl ring, resembling phenylalkylamines [67]. The distance between the two 
mentioned functional groups might seem enough for the molecule to undergo the necessary conformational changes 
to interact with both benzothiazepine and phenylalkylamine binding sites of the channels. However, the 
benzothiazepine and phenylalkylamine binding sites partially overlap with each other [65]. 
In this review some other compounds are also mentioned which can not be categorized clearly into any of 
the three major classes based on their chemical structure. These contain some structural motifs which presumably 
have the same function as the motifs mentioned earlier related to the major classes of the Ca2+ channel blockers. 
Mibefradil binds to the same binding site in cardiac membranes as verapamil and with a similar potency [80]. 
Mibefradil has the isopropyl group [67], the tertiary amine, and the Ca2+ chelating ester group. These functional 
groups might seem enough to interact with both the channel and the ion [78]. But according to our assumption, the 
orientation of these groups prevents the strong inhibition of the voltage-gated L-type Ca2+ channel. Monatepil has a 
sulphur-containing heteroatomic ring, but that contains no nitrogen. Instead, the “expected” nitrogen can be found in 
the amide group attached to this ring. This amide might chelate a Ca2+ ion, but not as strong as an ester group. The 
other parts of the molecule do not resemble any other aforementioned functional groups except the same piperazinyl 
ring which can be found in S-2150. Due to the above mentioned observations about the chemical structure, monatepil 
seems to be less potent as a Ca2+ channel inhibitor as S-2150. Bepridil has an isobutyl ester which might take the role 
of the isopropyl group mentioned above, but due to the low number of hydrophilic groups, the interaction between 
bepridil and Ca2+ is not plausible. Owing to the lack of Ca2+ chelating activity, it cannot be an effective L-type 
channel inhibitor [67]. AH-1058 is quite the opposite, thanks to the adjacent methoxy and nitro groups attached to an 
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aryl ring, the molecule can bind Ca2+. On the other hand, there are no molecular interaction sites binding to the 
channel itself. The structure of AP-792 shows absolutely no similarity to those mentioned in earlier sections. 
 
5. Interactions between simultaneous binding of different inhibitor classes (allosteric model) 
 
Nifedipine and verapamil inhibit the clentiazem binding to Ca2+ channels [81]. Binding studies showed a 
concentration-dependent positive allosteric interaction between [3H](+)-isradipine and mibefradil, but not with 
[3H](+)-isradipine and D600 enantiomers. Molecular and functional evidences point to an interaction between a 
dihydropyridine and mibefradil [82]. Semotiadil has a strong negative allosteric interaction with the three major 
classes of CCAs at their specific binding sites [83]. Based on radio ligand assays, verapamil inhibited binding of 
isradipine, but diltiazem stimulated the binding of isradipine in a temperature-sensitive manner [84]. Those binding 
residues being critical for the contact of the ligand receptor interactions are listed by Hockerman and coworkers [65]. 
Binding of diltiazem to L-type Ca2+ channels requires those residues overlapping with critical ones for 
dihydropyridine and phenylalkylamine block as well as residues unique to diltiazem. Channel-ligand interactions 
involve also residues which are only take part in binding one antagonist of the three major classes [65]. These facts 
indicate that the binding of the antagonists dynamically changes the binding regions of the L-type Ca2+ channel 
(mainly residues in IIIS6 and IVS6). Therefore, the binding of another class of CCA to the channel is altered. This 
was summarized in the allosteric model involving interactions between different binding sites [85]. 
 
6. Potential mechanisms behind the antiarrhythmic actions of CCAs 
 
CCAs can induce antiarrhythmic action by several mechanisms. 
1. Calcium overload occuring during cardiac ischemia [86] can lead to spontaneous Ca2+ release from the 
sarcoplasmic reticulum [87],[88]. This released Ca2+ is replaced by Na+ by the forward mode of the Na+/Ca2+ 
exchanger leading to the depolarization of the cell membrane [89]. This depolarization is called either early or 
delayed afterdepolarization (EAD or DAD) depending on their timing compared to the full repolarization of the cell 
membrane. EADs form before, while DADs are generated after the full repolarization [90]. These 
afterdepolarizations are well known triggering sources of cardiac arrhythmias. Large enough afterdepolarizations 
occurring in the vulnerable period (when those ion channels responsible for the upstroke of the AP can be opened) 
can evoke a triggered AP. This AP can manifest in a simple extrasystole but can be the trigger for a much more 
dangerous (sometimes lethal) rhythm disorders including torsade de pointes (TdP) type VF [91]. 
The reduction of inward calcium currents by CCAs (due to the inhibition of both L- and T-type calcium channels) 
results in reduced calcium influx to cardiomyocytes, therefore leading to calcium depletion, which according to the 
previous fact can have antiarrhythmic effect by reducing the risk of calcium overload. Verapamil was shown to 
suppress spontaneous or epinephrine-induced EADs and TdP in cats [92] and it suppressed the epinephrine induced 
ventricular premature complexes (VPCs) and TdP in humans as well [93]. Moreover, it was suggested that 
semotiadil inhibits Ca2+ release from Ca2+ stores or decrease the sensitivity of the contractile elements to Ca2+ on top 
of the ICa,L inhibition [71]. 
Those CCAs, possessing large inhibitory actions on other ion channels, might have increased antiarrhythmic 
properties. The reduction of fast sodium current (INa) and/or Na+/Ca2+ exchange current (INCX) (as with bepridil [94]) 
would reduce the risk of the development of triggered AP and the generation of afterdepolarizations, respectively. 
In rats with vitamin D3 induced calcium overload, fantofarone decreased the calcium content in the thoracic aorta, 
mesenteric artery and also in their heart [95]. 
2. The inhomogeneity of the repolarization times exists even in the healthy myocardium. That includes the 
transmural dispersion of repolarization (TDR) [96], the apico-basal gradient in repolarization [97] as well as the 
different repolarization times in left versus right ventricular muscle [98]. The increase of these inhomogeneities can 
lead to reentry arrhythmias [90]; therefore the reduction of TDR might be another important mechanism by which 
the antiarrhythmic action of CCAs can be mediated. This was observed in case of verapamil in a feline model of 
acquired long QT syndrome (LQTS) [92] as well as in patients with congenital LQTS [93]. A parallel and 
homogeneous prolongation in repolarization and refractoriness were thought to be essential for the antiarrhythmic 
effect of bepridil [99].  
3. The generation and propagation of action potentials (AP) in pacemaker tissues are largely mediated by L-type 
calcium channels. That is the reason why CCAs with low vascular selectivity (having remarkable action on 
myocardium as well) are very effective in supraventricular tachyarrhythmias (AF and atrial flutter (AFL)). Namely, 
these CCAs effectively reduce the atrioventricular (AV) conduction leading to a negative dromotropic effect. For a 
recent review on AF see ref [100]. 
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4. Prolongation of the recovery from inactivation of calcium channels was described with verapamil [54], bepridil 
[35], semotiadil and also with diltiazem [39]. This alteration of channel behavior can also contribute to the 
antiarrhythmic action of CCAs by increasing the refractory period (RP) of nodal tissues. This mechanism, similarly 
to the negative dromotropic effect of CCAs can be especially useful against supraventricular tachyarrhythmias and 
lead to the reduction of the ventricular rate (VR). 
5. The amplitude of systolic calcium transients depends on at least two factors. One of them is the amplitude of the 
trigger for the calcium release from the sarcoplasmic reticulum, namely the calcium influx through mainly the L-type 
calcium channels of the sarcolemma. The other one is the calcium content of the intracellular calcium stores not to 
mention the sarcoplasmic reticulum gain which relates the amount of released calcium to the amount of the 
triggering calcium [101],[102]. These two factors are both reduced by CCAs, therefore it is not surprising that CCAs 
lead to the decrease of calcium transient amplitudes (for verapamil and mibefradil [103] for D600 [104], for 
SR33805 [40], for KT-362 [105] and for AH-1058 [106]). The major ATP using process in myocytes is the 
contractile machinery, the activity of which depends on intracellular calcium. Therefore, the previously mentioned 
reduction of intracellular calcium level will reduce adenosine triphosphate (ATP) consumption. Similarly, the 
reduction of VR will lead to an energy sparing effect and a reduction in ATP usage. Arrhythmias can develop in 
ischemic myocardium in which the ATP levels drop, therefore the preservation of ATP by CCAs could be another 
reason of their antiarrhythmic action. 
Myocardial oxygen consumption can be an indirect measure of the metabolic activity of the myocardium and 
therefore it is likely to be directly proportional with ATP requirement. CCAs reportedly reduce cardiac oxygen 
consumption (for verapamil [107], for fantofarone [108], for KT-362 [42] and for bepridil [109], [110]) therefore 
again leading to a possible antiarrhythmic action. 
The mechanism how the reduction of intracellular ATP level can lead to arrhythmias can be related to the function of 
ATP dependent potassium channels [111]. 
6. CCAs exert useful hemodynamic actions including vasodilatation leading to reduced preload and afterload, 
respectively. These will reduce the work of the heart, causing again a potential ATP sparing effect. Moreover, the 
increase in coronary flow (CF) can be found with CCAs. This effect is often not homogenous but a redistribution of 
the available CF can be seen. In some cases, CF of the ischemic area is increased improving the myocardial oxygen 
supply/oxygen requirement ratio [112] which is again beneficial. 
7. Many CCAs were shown to inhibit not only calcium channels but also other ion channels. Inhibitions of INa and 
INCX have already been mentioned above to reduce the calcium overload and its arrhythmogenic consequences. 
Sodium channel inhibition was observed with many CCAs although in most cases only indirect, maximal rate of 
depolarization (Vmax) measurements are available (for verapamil [113], for diltiazem [114], for siratiazem [115], for 
semotiadil [116], for levosemotiadil [117], for KT-362 [118], for mibefradil [119], for AH-1058 [38] and for bepridil 
[33]). 
Potassium channels were also reduced by some nonselective CCAs. The reduction of major repolarizing currents 
including transient outward potassium current (Ito), IK and inward rectifier potassium current (IK1) would lead to the 
prolongation of AP thereby an increase in the RP. BRL-32872 for instance inhibits IKr much more potently compared 
to ICa,L [41]. The increase of the RP together with the reduction of several potassium currents were observed with 
bepridil (see later). The prolongation of the RP induced by many CCAs on the level of nodal tissues as well as atrial 
and ventricular myocardium will lead to antiarrhythmic action as reentry will occur less likely. 
There are several reports about the inhibition of other potassium currents by some CCAs. Some of these are mostly 
expressed in the atrial muscle as acetylcholine-activated potassium current (IK,Ach) and the ultrarapid component of 
delayed rectifier potassium current (IKur). The reduction of IK,Ach together with the increase in atrial effective 
refractory period (ERP) was reported with levosemotiadil [33], [117] and also with bepridil [120],[121]. The native 
current of IKur was blocked by verapamil in human atrial cells [122] and also by bepridil [33] and diltiazem [122] 
although in higher than therapeutic doses. 
Bepridil blocked heterologously expressed sarcolemmal ATP dependent potassium channels, but the drug opened 
mitochondrial ATP dependent potassium channels which latter is believed to be cardioprotective [123]. Both 
levosemotiadil and semotiadil reduced ATP dependent potassium current (IK,ATP) in high doses [124]. Interestingly, 
the infarct size reducing effect of mibefradil in isolated, Langendorff-perfused rat hearts [125] and in anesthetized 
pigs [126], [127] was attributed at least in part to its IK,ATP activating property. 
Sodium activated potassium current (IK,Na) was reduced by verapamil and levosemotiadil [127] as well as by bepridil, 
which was suggested to be responsible for the non reverse-rate dependent AP lengthening effect of bepridil [127]. 
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7. Proarrhythmic actions of CCAs 
 
Like other pharmacological antiarrhythmic intervention (particularly class III agents), some CCAs may also 
be proarrhythmic. The redistribution of CF is one of these unwanted actions. Verapamil caused a coronary steal from 
the ischemic area of the myocardium [128] thereby likely aggravated the reduction of oxygen supply, ATP 
production and levels. Coronary dilation itself, regardless of its position (ischemic or non-ischemic area of the 
myocardium), is not necessary beneficial especially if it occurs during reperfusion as it could amplify the risk of the 
development of reperfusion arrhythmias. Some CCAs including D600 was found to be arrhythmogenic as it induced 
a prolongation of the APD and provoked EADs in a special model of papillary muscles of guinea-pig hearts [129]. In 
Langendorff-perfused rabbit hearts D600 at higher doses when it also inhibits INa converted ventricular tachycardia 
(VT) to slow VF (11.9±2.3 Hz) [130]. Bepridil was also reported to evoke EAD at long cycle length (CL) in canine 
Purkinje fibers [131] and it also increased TDR by mainly lengthening M cell APD in canine wedge preparations 
[132]. Moreover, in vivo animal studies reported arrhythmogenic action of bepridil during coronary occlusion (but 
not during reperfusion) [133], [134]. VT, prolongation of QTc interval and TdP were detected with bepridil treatment 
in permanent AF patients, while no ventricular arrhythmias were seen with amiodarone [134]. Anipamil was also 
found arrhythmogenic at least in pentobarbitone-anesthetized pigs where it increased the occurrence of VT and VF 
[135], [136]. In rats with healed infarcts and ventricular dysfunction, 8-week-long anipamil treatment aggravated left 
ventricular dilatation and remodeling, thereby reduced survival [136]. 
Verapamil, together with other CCAs, is on the list of drugs to avoid in the treatment of Brugada syndrome 
due to their potential proarrhythmic action [137], [138]. Bepridil is an exception but due to its Ito and IK,Ach and 
certainly not its calcium channel blocking action [139]. CCAs should also be avoided in the treatment of short QT 
syndrome as in some genetic, congenital forms of the disease (SQT4 and 5) the calcium channels are already conduct 
a smaller current [140], [141]. Moreover, together with other drugs, verapamil is used to model early repolarization 
in animal studies [142]. However, verapamil was effective but unfortunately it did not prevent sudden death [143]. 
 
8. Additional electrophysiological effects of CCAs 
 
8.1. Phenylalkylamines 
 
Verapamil 
Verapamil (Fig. 2.) is the best known phenylalkylamine which is used in antiarrhythmic treatment even 
today although it is not a new compound at all. Actually, it was probably the first CCA introduced to human clinical 
treatment. It was considered to be a coronary vasodilator therefore its use started as an antianginal agent in 1962 in 
Germany [144]. 
The therapeutic plasma concentration of free verapamil (not bound to proteins) in humans is between 20-800 nM 
[145], although the mean myocardial to plasma concentration ratio was approximately seven suggesting 
accumulation of the drug in the heart [146]. Indeed, verapamil can accumulate in canine myocardium in a chamber 
specific manner showing greater accumulation in the ventricles compared to the atria without having left versus 
right-sided specific distribution [147]. 
Apart from the calcium channel inhibition, verapamil is likely to inhibit sodium channels as Vmax, which is often 
used as an indirect measure of INa, was reduced by the drug in supratherapeutic concentrations (IC50 of 10 µM) in 
guinea-pig [20]. In isolated canine Purkinje fibers 6 µM verapamil or above decreased Vmax, AP amplitude (APA) 
and conduction velocity [148]. The most pronounced effect on Vmax was observed in guinea-pig right ventricular 
muscle where 1 µM evoked 42 % reduction [113]. 
Potassium channels were also reduced by verapamil. In guinea-pig ventricular myocytes 1 and 5 µM verapamil 
reduced IKr by 50 and 87 %, respectively [149]. The slow component of the delayed rectifier potassium current (IKs) 
was recuced by 18 and 40 % in the presence of 1 and 5 µM verapamil, respectively [149]. Verapamil exerted an 
inhibitory action on expressed potassium channel proteins including human ether-a-go-go (hERG) channels in the 
possible therapeutic level in the myocardium [150], [151] and Kv1.5 (responsible for IKur) channels with an IC50 of 
5.1 µM [151].The native current of IKur was also blocked by verapamil in human atrial cells from as low as 1 µM 
[122]. Verapamil blocked IK,Na in guinea-pig ventricular cells with an IC50 of 3.36 µM [127]. Verapamil reduced the 
open probability of large-conductance calcium-activated potassium channels (BKCa) in rat aortic myocytes with a 
dissociation constant of 4.1 µM. Results suggested an open channel block [152]. 
In guinea-pig cardiomyocytes the APD was reduced by 45 % in 10 µM verapamil, which also reduced the plateau of 
the AP [153]. In contrast, verapamil slightly increased APD in guinea-pig papillary muscle [154]. The APD increase 
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by verapamil was also seen in spontaneously beating rabbit SA nodal cells together with the reduction of Vmax and 
APA [155]. 
The effects of verapamil in nodal tissues included an increase in CL, maximal diastolic potential (MDP) and APD 
but a reduction in both Vmax and APA on rabbit SA node tissue [156]. 
 
D600 (gallopamil) 
D600 (Fig. 2.) had a peak plasma concentration of 61-77 ng/ml (equivalent to approximately 120-150 nM) 
in patients taking 50 mg D600 three times a day for 28 days [157]. Myocardial concentrations could be even higher 
as, similarly to verapamil, D600 can be accumulated, at least in guinea-pig left auricles, to up to six times [158]. 
D600 is a methoxy derivative of verapamil which was also shown to reduce INa. In cultured chick heart cells 
INa was reduced by D600 with an IC50 of 30 µM [159]. 10 µM D600 had no effect on Vmax in guinea-pig ventricular 
cells [20]. In contrast, the same study reported 50 % reduction by 10 µM verapamil suggesting a less potent INa 
inhibition by D600. 
Ito of rat ventricular cardiomyocytes was reduced with an IC50 of 3 µM by D600 [160]. 
D600, at 1 and 10 µM, decreased the open probability of BKCa channels by 37 and 84 %, respectively, in rat aortic 
myocytes which was more potent compared to that of verapamil [152]. 
 
Tiapamil (Ro 11-1781) 
Tiapamil (Fig. 2.), similarly to verapamil, inhibited calcium-induced contractions in rat renal artery, canine 
coronary artery and rabbit main pulmonary artery in a dose-dependent manner [161]. Sodium channel inhibition was 
suggested in guinea-pig papillary muscles where tiapamil reduced Vmax at concentrations above 1 µM with an IC50 
value of 70 µM in a use-dependent manner whereas verapamil was less potent [162] at least in that study. Similarly, 
tiapamil caused marked alterations of the normal sodium AP, namely the reduction of Vmax and the prolongation of 
plateau phase [163]. 
 
Anipamil 
Only indirect effects are available suggesting the calcium channel inhibitory action of anipamil (Fig. 2.) as 
the drug dose-dependently reduced the contractile force of Langendorff-perfused rat hearts with an IC50 of 100 nM. 
Comparison to the other phenylalkylamines is difficult as rat data are not available but anipamil was slightly less 
potent compared to D600 (IC50 of 60 nM in guinea-pig left auricles) and its negative inotropic action was the same as 
that of verapamil (IC50 of 100 nM in isolated guinea-pig left atria). Anipamil was found to be selective to cardiac 
muscle and had no effect on coronary smooth muscle up to 100 µM in isolated rabbit heart. In contrast, both 
verapamil and D600 reduced heart rate (HR) up to asystole and evoked coronary spasm together with their negative 
inotropic effect. The reduction in contractility was only partially reversible and long lasting (up to 12 hours) with 
anipamil in contrast to verapamil and D600 whose negative inotropic effect was completely reversible within 3 hours 
of washout [164]. 
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FIG. 2. Chemical structure and IUPAC name of phenylalkylamines. The first and best known one is the circled 
verapamil. 
Verapamil, 2-(3,4-dimethoxyphenyl)-5-[2-(3,4-dimethoxyphenyl)ethyl-methylamino]-2-propan-2-ylpentanenitrile  
D600, 5-[2-(3,4-dimethoxyphenyl)ethyl-methylamino]-2-propan-2-yl-2-(3,4,5-trimethoxyphenyl)pentanenitrile  
Tiapamil, N-[2-(3,4-dimethoxyphenyl)ethyl]-3-[2-(3,4-dimethoxyphenyl)-1,1,3,3-tetraoxo-1,3-dithian-2-yl]-N-
methylpropan-1-amine  
Anipamil, 2-(3-methoxyphenyl)-2-[3-[2-(3-methoxyphenyl)ethyl-methylamino]propyl]tetradecanenitrile  
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8.2. Benzothiazepines 
 
Diltiazem 
Diltiazem (Fig. 3.) is the prototype of benzothiazepine structure type CCAs. 
The human therapeutic plasma concentration of diltiazem is between 100-700 nM, but after correction to protein 
binding it was only 10-50 nM [145]. 
Diltiazem reduced IKur in human atrial myocytes in a dose-dependent manner with an IC50 of 11.2 µM, which was 
again less potent compared to that of verapamil (IC50 of 3.2 µM) [122], [165]. 
Glibenclamide-sensitive potassium currents in Xenopus oocytes were blocked by diltiazem in a stereoselective 
manner with IC50 values of 4.2, 13.3, 35.8 and 75.9 µM for (+)-trans, (-)-trans, (-)-cis and (+)-cis, respectively [124]. 
Interestingly, this order of blocking potency of the stereoisomers of diltiazem was exactly the opposite in case of ICa,L 
inhibition. 
9 µM IC50 value was reported for INa inhibition in guinea-pig ventricular cells, however, L-cis diltiazem was applied 
instead of the racemic molecule in that study [166]. Indirect measurements about the INa blocking action of diltiazem 
(Vmax and sometimes APA determination of fast APs) are available in cat by 2.2 µM [114], in guinea-pig by 22 µM 
[167], in dogs by 11 µM [168] and also in human from 30 µM [169]. When compared to verapamil, diltiazem was 
again less potent in reducing Vmax in canine Purkinje fibers and in guinea-pig ventricular muscle as well. 
Regarding the effects of diltiazem on the duration of fast APs, one can find a slight increase in guinea-pig papillary 
muscles [154], increased APD80 in ferret right ventricular papillary muscles [25]; no change in rabbit ventricular 
APD up to 10 µM [170] and in feline right ventricular fibers by 2.2 µM diltiazem [114]; and also reduction of APD 
in guinea-pigs ventricular muscle [167], in canine Purkinje fibers [171] and in human ventricular myocardium [169] 
by 110, 1 and 10 µM diltiazem, respectively. The effect of diltiazem on early repolarization duration of the fast APs 
corresponding to the plateau phase (APD20 and APD30) is equivocal in the literature as diltiazem reduced these 
values and depressed the plateau potentials in ferret right ventricular papillary muscles [25], canine ventricular 
muscles and Purkinje fibers [168]. 
Comparing diltiazem to verapamil, similar effects were found on AV nodal conduction time (CT) (greater increase 
during tachycardia compared to that during sinus rhythm (SR)) but the tau-on was shorter for diltiazem [172]. 
Similar actions were detected in canine ischemia induced VF with verapamil [173], [174]. 
Diltiazem was less effective compared to verapamil in most of their evoked actions. This was the case in reducing 
Vmax in canine Purkinje fibers [148], [168] and in guinea-pig ventricular muscle [113], [167]; in reducing inotropy in 
dogs [175], [176] and in guinea-pig myocardial preparations [154]; in reducing chronotropy on rabbit SA node tissue 
[156], in anesthetized dogs [177] and in guinea-pig myocardial preparations [154]; in exerting vasorelaxing effect 
[154], [176]. Similar antiarrhythmic effect was observed with twice as large dose of diltiazem compared to verapamil 
in open-chest anesthetized dogs [178]. 
In contrast to the previously mentioned results, the negative chronotropic action of diltiazem was more potent than 
that of verapamil in anesthetized dogs [177] and in canine right atrium [175]. The vascular selectivity of verapamil 
was slightly lower compared to that of diltiazem [176]. 
 
Siratiazem (LR-A113) 
Siratiazem (Fig. 3.) was designed to be resistant to N-demethylation and had 1.6-1.9 times longer half-life 
in conscious rats after both oral and intravenous administration without a major increase in its bioavailability [179]. 
In depolarized ovine coronary artery rings potassium-stimulated calcium uptake was also inhibited by siratiazem and 
diltiazem with similar potencies [30]. Siratiazem dose-dependently (1-10 µM) reduced APA, Vmax, APD50 and APD90 
values of ovine Purkinje fibers without affecting resting membrane potential (RMP) [115]. 
 
Clentiazem (TA-3090) 
Clentiazem (Fig. 3.) is a chloride containing diltiazem derivative having peak plasma levels of 17 and 
19 ng/ml (approximately 30-33 nM) in patients with essential hypertension [180]. Clentiazem antagonized 
contractions of rabbit myocardium with the same potency compared to diltiazem (IC50 values of 43 and 39 µM, 
respectively) but in a longer-lasting manner [28]. On isolated human right ventricular trabeculae clentiazem evoked 
negative inotropic actions with an EC50 of 8.8 µM which was similar to that of diltiazem (7.2 µM EC50) [27]. On 
isolated rabbit tissues clentiazem was more vasoselective than diltiazem [28]. Clentiazem proved to be more 
effective than diltiazem but less potent than verapamil in reducing the spontaneous rate of rabbit SA nodal tissue. 
Clentiazem reduced Vmax and APA while increased MDP and APD and the magnitude of these effects was again 
intermediate compared to diltiazem (being the least potent) and verapamil (being the most potent) [156]. In vitro 
experiment on rabbit hearts showed that, similarly to diltiazem, clentiazem (10-1000 nM) caused a dose-dependent 
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increase in AH interval without affecting HV interval. In AV and SA nodal cells 1 µM clentiazem reduced APA, 
Vmax, APD50, APD20 and MDP without changing APD90. In AV node the drug prolonged ERP and up to 10 µM it did 
not change ventricular AP [170]. In dogs, sustained negative chronotropic effects were recorded in high dose and 
these were correlated well with myocardial clentiazem levels [181]. 
Similarly, clentiazem was more potent in lowering mean arterial pressure (MAP) without evoking a positive reflex 
chronotropic action in dogs compared to diltiazem [182]. Clentiazem increased coronary blood flow just as diltiazem 
[183] but its effect was more prolonged [184] and showed higher selectivity for coronary arteries [183]. 
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FIG. 3. Chemical structure and IUPAC name of benzothiazepines. The first and best known one is the circled 
diltiazem. 
Diltiazem, [(2S,3S)-5-[2-(dimethylamino)ethyl]-2-(4-methoxyphenyl)-4-oxo-2,3-dihydro-1,5-benzothiazepin-3-yl] 
acetate 
Clentiazem, [(2S,3S)-8-chloro-5-[2-(dimethylamino)ethyl]-2-(4-methoxyphenyl)-4-oxo-2,3-dihydro-1,5-
benzothiazepin-3-yl] acetate  
Siratiazem, [(2S,3S)-2-(4-methoxyphenyl)-5-[2-[methyl(propan-2-yl)amino]ethyl]-4-oxo-2,3-dihydro-1,5-
benzothiazepin-3-yl] acetate 
S-2150, Acetic acid 8-chloro-2-(4-methoxy-phenyl)-5-{3-[4-(2-methoxy-phenyl)-piperazin-1-yl]-propyl}-4-oxo-
2,3,4,5-tetrahydro-benzo[b][1,4]thiazepin-3-yl ester 
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8.3. Other CCAs 
 
Semotiadil (SD-3211) 
Semotiadil (Fig. 4.) blocked glibenclamide-sensitive potassium current in Xenopus oocytes more potently 
compared to verapamil (IC50 values of 10 and 60 µM, respectively) [124]. 
Semotiadil, but not diltiazem, inhibited the norepinephrine-induced transient contraction, even in the absence of 
external Ca2+ and in nifedipine-treated muscles, suggesting an inhibition of Ca2+ release from Ca2+ stores or decrease 
in sensitivity of the contractile elements to Ca2+ on top of the ICa,L inhibition [71]. 
Semotiadil (1-10 µM) reduced APD in a dose-dependent manner without affecting the RMP or Vmax in guinea-pig 
papillary muscles. The Vmax of slow responses was inhibited only above 1 µM [116]. 
Semotiadil exerted potent inhibition on both depolarization-induced (evoked by KCl) and ligand-induced (histamine 
and norepinephrine) contractions in porcine coronary arteries [6], in isolated rat aortas [71] and also in isolated 
canine coronary arteries [185]. The inhibition of potassium-induced contractions was usually more potent compared 
to both diltiazem and verapamil. 
 
Levosemotiadil (SD-3212) 
Levosemotiadil (Fig. 4.) is the stereoisomer of semotiadil with an approximate plasma level of 350 nM 
[117]. Levosemotiadil inhibited ICa,L and INa in a dose-dependent manner with IC50 values of 1.3 and 3.9 µM, 
respectively, in guinea-pig atrial cells. The steady-state inactivation curves of both currents were shifted to more 
negative potentials by 1 µM levosemotiadil [33]. Vmax inhibition by levosemotiadil was described in guinea-pig right 
ventricular papillary muscles (3 µM and above in a use-dependent manner) [186], in canine tissue (0.3-3 µM in a 
use- and concentration-dependent manner) [117] and in rabbit papillary muscles (3-10 µM in a use- and 
concentration-dependent manner) [187]. 
Levosemotiadil blocks IK,Na in guinea-pig ventricular cells with an IC50 of 0.53 µM [127]. Glibenclamide-sensitive 
potassium channels (IK,ATP) in Xenopus oocytes were blocked slightly more potently by levosemotiadil compared to 
semotiadil (IC50 values of 9 and 11 µM, respectively) [124]. 
IK,Ach was potently inhibited with an IC50 of approximately 0.29 µM. Carbachol induced AP shortening was reversed 
by 0.1-1 µM levosemotiadil in a dose-dependent manner in guinea-pig atrial cells [33]. 
Levosemotiadil significantly increased APD in canine tissue (1-3 µM) [117] and in rabbits (endocardial monophasic 
AP and in papillary muscles in the range of 3-10 µM) [187]. The prolongation of AP did not vary with stimulation 
frequency and levosemotiadil did not influence APA or RMP [187]. Similarly, levosemotiadil increased right atrial 
ERP with the same extent regardless of the CL [117]. 
Levosemotiadil (1-10 µM) evoked similar actions seen with semotiadil but not with diltiazem, suggesting an 
inhibition of Ca2+ release from Ca2+ stores or decrease in sensitivity of the contractile elements to Ca2+ [71]. 
 
SR 33805 
SR 33805 (Fig. 4.) inhibited the high potassium depolarization-induced, sustained increases in intracellular 
calcium level and force with IC50 values of 3.2 and 49.4 nM, respectively [188]. It also sensitized myofilaments to 
calcium as in the medial strip of the porcine coronary artery SR33805 caused a leftward shift of both the intracellular 
calcium level-force and the intracellular calcium level-myosin light chain phosphorylation curves [188]. Similarly, 1-
10 µM SR33805 induced the sensitization of the myofilaments to calcium in ventricular myocytes from both normal 
[40] and from end-stage heart failure (HF) rat hearts [189] without increasing the calcium transient amplitude. 
SR33805-induced sensitization of myofilament activation was found to be associated with a slight increase in myosin 
light chain-2 phosphorylation and a more significant decrease on troponin I phosphorylation, which latter was related 
to inhibition of protein kinase A activity by SR33805 [189]. SR33805 reduced APD and the amplitude of the 
calcium transient in rat ventricular myocytes. 10 nM SR33805 enhanced the amplitude of unloaded cell shortening 
and facilitated its relaxation. Moreover, it induced a significant increase in maximal calcium-activated force [40]. 
 
BRL-32872 
BRL-32872 (Fig. 4.) inhibited IKr and ICa,L with IC50 values of 0.028 and 2.8 µM, respectively, but had a 
limited effect on IK1 in isolated guinea-pig myocytes [41]. BRL-32872 evoked an unusual effect on APD. AP 
prolongation with 0.3-10 µM BRL-32872 had a bell-shape with the largest prolongation of 24-25 % occurring at 
1 µM in both guinea-pig papillary muscle [41] and in canine Purkinje fibers [190]. Moreover, in guinea-pig papillary 
muscle the extent of prolongation did not depend on stimulation CL and no reverse-rate dependence was found [41]. 
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FIG. 4. Chemical structures and IUPAC names of benzothiazepine- (above) or phenylalkylamine-like (below) 
compounds and one with similarity to both (up right). 
Semotiadil, (2R)-2-[2-[3-[2-(1,3-benzodioxol-5-yloxy)ethyl-methylamino]propoxy]-5-methoxyphenyl]-4-methyl-
1,4-benzothiazin-3-one 
Levosemotiadil, 2-[2-[3-[2-(1,3-benzodioxol-5-yloxy)ethyl-methylamino]propoxy]-5-methoxyphenyl]-4-methyl-1,4-
benzothiazin-3-one 
KT-362, 1-(3,4-dihydro-2H-1,5-benzothiazepin-5-yl)-3-[2-(3,4-dimethoxyphenyl)ethylamino]propan-1-one 
Fantofarone, N-[2-(3,4-dimethoxyphenyl)ethyl]-N-methyl-3-[4-(2-propan-2-ylindolizin-1-
yl)sulfonylphenoxy]propan-1-amine 
SR 33805, [2-(3,4-Dimethoxy-phenyl)-ethyl]-{3-[4-(3-isopropyl-1-methyl-1H-indole-2-sulfonyl)-phenoxy]-propyl}-
methyl-amine 
BRL 32872, N-(3,4-dimethoxyphenyl)-N-[3-[2-(3,4-dimethoxyphenyl)ethyl-methylamino]propyl]-4-nitrobenzamide 
 
KT-362 
In isolated papillary muscles of guinea-pig 3-30 µM KT-362 (Fig. 4.) caused a dose- and use-dependent 
decrease in Vmax without changing RMP, suggesting the inhibition of INa. 
KT-362 (1-30 µM) decreased both systolic and diastolic intracellular calcium concentration in a dose- and use-
dependent manner in cultured neonatal rat ventricular cells aggregates. 30 µM KT-362 increased time to peak of the 
Ca2+ transient, while the half-life of the calcium transient was prolonged at 10 µM and above. These effects of KT-
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362 on Ca2+ transients could be mimicked by simultaneous application of 1 µM D600 and 10 µM ryanodine, 
suggesting that KT-362 inhibits both sarcolemmal calcium channels and calcium release channels of the 
sarcoplasmic reticulum [105]. Other studies also support the inhibition of calcium release channels of the 
endoplasmic reticulum (inositol-triphosphate receptor) by KT-362 in the micromolar range in rabbit aorta [191] and 
in canine femoral arteries [192]. 
 
Mibefradil (RO 40-5967) 
The therapeutic plasma concentration of mibefradil (Fig. 5.) was in the range of 10-1000 ng/ml 
(approximately 0.02-2 µM) [193]. 
Not only calcium channels were blocked by mibefradil as in CHO cells transfected with human Kv1.5 mibefradil 
showed a dose-, use- and voltage-dependent inhibition with an IC50 of 0.78 µM. Recovery from inactivation was 
faster with mibefradil [194]. Mibefradil inhibited the expressed hERG and KvLQT1/IsK channel currents with IC50 
values of 1.43 and 11.8 µM, respectively [150]. Mibefradil blocked the delayed rectifier potassium current, the 
hERG potassium current and IK1 with IC50 values of 0.3, 0.7 and 5.6 µM, respectively, in human myoblasts [195]. 
Nav1.5, the cardiac isoform of sodium channels expressed in HEK cells, was blocked by mibefradil with an IC50 
value of 1 µM [119] and with IC50 values of 0.5 and 2.9 µM from holding potentials of -100 and -130 mV, 
respectively [196]. In murine B cell lines mibefradil blocked voltage-gated potassium current and large-conductance 
background potassium current with IC50 values of 1.9 and 2.3 µM, respectively. Interestingly, calcium-activated 
potassium current was increased by 0.5-5 µM mibefradil as the drug increased both calcium sensitivity and maximal 
activity of these channels. At high concentrations (>10 µM), mibefradil inhibited calcium-activated potassium 
channel current in a voltage-dependent manner [197]. 
Several studies described the effects of mibefradil on APs. 100 nM mibefradil reduced APA and AP firing rate 
(sometimes even stopped the activity) as well as shifted MDP to more positive potentials in rabbit SA node cells 
[51]. In 10 µM it reduced Vmax and phase 4 slope, without affecting APD [48]. The effect of mibefradil on APD is 
variable. No effect was detected in human atrial myocytes in 1-10 µM [153] and in 0.1-1 µM on monophasic APDs 
in Langendorff-perfused rabbit heart [153]. Reduction of APD was observed in guinea-pig ventricular cells in 10 µM 
[153]. In contrast, mibefradil (3-10 µM) increased APD in canine Purkinje fibers [52]. The reduction of the plateau 
of the AP was described by 1 and 10 µM mibefradil in isolated guinea-pig ventricular cardiomyocytes and in human 
atrial myocytes [153]. Same was seen in canine Purkinje fibers by doses of 3-10 µM [52]. Indicating the inhibition of 
INa, 10 µM mibefradil reduced overshoot potential and APA in isolated guinea-pig cardiomyocytes but had no effect 
on the RMP [153]. 
 
Bepridil (CERM-1978) 
The therapeutic plasma concentration of bepridil (Fig. 5.) is approx. 2 µM [198] although the unbound 
concentration of bepridil is much lower, approximately 15 nM [199]. Oral doses of 200, 300 and 600 mg/day bepridil 
given to volunteers resulted in the peak plasma levels of 0.28, 0.44 and 0.97 µg/ml (0.76, 1.2 and 2.6 µM), 
respectively [200]. 
10-100 µM bepridil evoked calcium sensitizing action and increased force and ATPase activity in skinned porcine 
trabeculae [201]. In cultured neonatal rat ventricular cells 10 µM bepridil sensitized myofilaments to calcium [104]. 
1 µM bepridil reduced oxidative phosphorylation in rabbit heart mitochondria by 50 % [202]. 
INa was also reduced by bepridil in neonatal rat cells with an IC50 of 30 µM (much less potently compared to ICa,L 
inhibition). INa steady-state inactivation was shifted to more negative potentials and recovery from inactivation was 
slowed down just as with ICa,L [35]. In guinea-pig ventricular cells INa inhibition by bepridil was more potent as the 
IC50 was 20 µM [203]. INa in guinea-pig atrial cells was even more sensitive to bepridil (IC50 of 4.34 µM) which is 
similar to that seen by levosemotiadil [33]. Interestingly, when 10 µM bepridil was applied for 24 h on isolated 
neonatal rat cardiomyocytes it augmented INa with 50 % by inhibition of calmodulin action leading to a decreased 
degradation of the Nav1.5 α subunit while the same dose applied for 3 min reduced INa by 20 % [204]. 
Sodium/calcium exchange was reduced by only supratherapeutic bepridil doses (IC50 of 30 µM) in cardiac 
sarcolemmal membrane vesicles and bepridil acted mode-dependently as the calcium extrusion (forward mode) was 
inhibited more effectively [205]. In guinea-pig ventricular cells INCX was more sensitive to bepridil (IC50 of 8.1 µM) 
[94]. 
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FIG. 5. Chemical structures and IUPAC names of various compounds with calcium channel antagonist action. 
Mibefradil, [(1S,2S)-2-[2-[3-(1H-benzimidazol-2-yl)propyl-methylamino]ethyl]-6-fluoro-1-propan-2-yl-3,4-dihydro-
1H-naphthalen-2-yl] 2-methoxyacetate  
Monatepil, N-(6,11-dihydrobenzo[c][1]benzothiepin-11-yl)-4-[4-(4-fluorophenyl)piperazin-1-yl]butanamide  
Bepridil, N-benzyl-N-[3-(2-methylpropoxy)-2-pyrrolidin-1-ylpropyl]aniline  
AH-1058, 4-Dibenzo[a,d]cyclohepten-5-ylidene-1-[3-(3-methoxy-2-nitro-phenyl)-allyl]-piperidine 
AP-792, 1-(4-Cyclohexyl-butyl)-4-dibenzo[a,d]cyclohepten-5-ylidene-piperidine 
 
HCN4 channels (underlying “funny” pacemaker current) expressed in HEK cells were also blocked by bepridil with 
an IC50 of 4.9 µM whereas verapamil was much less potent inhibitor of those channels (IC50 of 45 µM) [206]. 10 µM 
bepridil reduced “funny” pacemaker current in rabbit sinus node cells [207]. 
Regarding potassium currents, bepridil influenced all major cardiac potassium currents. Atrial potassium currents, 
like the current of expressed hKv1.5 channels (IKur) in HEK cells and IK,Ach in guinea-pig atrial cells were inhibited 
with IC50 values of about 7 and approximately 0.75 µM, respectively [33], [208]. The inhibition of IK,Ach by bepridil 
was less potent compared to that of levosemotiadil (IC50 of 0.3 µM). The carbachol-induced AP shortening was 
reversed by levosemotiadil more potently compared to bepridil [33]. 
Similarly to what was observed with INa, long-term bepridil treatment (12 h, between 0.3-30 µM) increased the 
protein level of Kv1.5 channels in a concentration-dependent manner with an IC50 of 1 µM by delaying the 
degradation process of Kv1.5 channel proteins acting at the endoplasmic reticulum as a chemical chaperone. The 
Kv1.5 current measured as 4-AP sensitive current was increased by 3 µM bepridil to 300 % of control [209]. 
10 µM bepridil completely blocked Kir6.2+SUR2A channels (underlying IK,ATP) expressed in HEK 293 cells, but the 
drug opened mitochondrial KATP channels thereby promoted cardioprotective action [123]. In follicle-enclosed 
Xenopus oocytes IK,ATP was blocked by bepridil with an IC50 of 7.6 µM, more effectively compared to verapamil 
(IC50 of 60 µM) but to the same extent as with levosemotiadil and semotiadil (IC50 values of 9 and 11 µM, 
respectively [124]. IK,Na in guinea-pig ventricular cells was reduced by bepridil with an IC50 of 0.51 µM, which can 
be the reason of the non reverse-rate dependent AP lengthening effect of the drug [127]. 
In guinea-pig ventricular myocytes 1-20 µM bepridil increased APD due to inhibition of IK and IK1 [210] but others 
found that neither IK nor IK1 was sensitive to bepridil up to 100 µM [35]. In sheep Purkinje fibers IK, IK1 and Ito was 
reduced by bepridil to various extent. Outward IK1 was reduced by 30 % in 1.8 µM bepridil, Ito was reduced with an 
IC50 of 2.5 µM and IK was also reduced by 10 µM [211]. In contrast, 10 µM bepridil had no effect on IK in rabbit 
sinus node cells [207]. In HEK cells expressing KCNQ1 and KCNE1 channel proteins (underlying IKs) bepridil 
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reduced the current with IC50 of 5.3 and 2.5 µM when 250 and 1000 ms long depolarizing pulses were applied, 
respectively. This suggests a greater affinity of binding to the closed channel [212]. Others found an IC50 of 10 µM 
for expressed KvLQT1/IsK channels mediated currents in COS cells [150]. Native IKs in guinea-pig ventricular cells 
was blocked by bepridil with an IC50 of 6.2 µM [213]. hERG channels expressed in HEK cells were blocked by 
bepridil with an IC50 of 26 nM [44] whereas in COS cells the IC50 value was 0.55 µM [150]. Native IKr currents in 
guinea-pig ventricular cells were reduced with an IC50 of 13.2 µM [213], less potently as expressed hERG protein. 
Moreover, it was suggested that bepridil can also inhibit IK,Ach [120]. 
 
AH-1058 
In isolated guinea-pig cardiomyocytes AH-1058 (Fig. 5.) dose-dependently reduced the amplitude of the 
calcium transient [106] and 10 µM AH-1058 blocked INa by 15 % without reducing IKr, IKs or IK1. In coronary-
perfused right ventricular guinea-pig tissue preparations 10 µM AH-1058 shortened the APD with little effect on the 
RMP, Vmax and overshoot potential. Contractile force was reduced by 0.1-10 µM AH-1058 in a dose-dependent 
manner [106]. 
 
9. Antiarrhythmic actions of certain CCAs 
 
Out of the compounds discussed in this review only three (verapamil, diltiazem and bepridil) have a licence for 
medical use according to the U.S. Food and Drug Administration and only 9 of them was tested in medical treatment 
in human volunteers and/or patients (see Tables 4-6 below for a summary). 
 
9.1. Phenylalkylamines 
 
Verapamil 
Animal studies with verapamil 
The antiarrhythmic effect of verapamil was observed in various animal models including guinea-pig [172], 
rabbit [214], cat [92], pig [135], [215] and dog [174], [178]. Verapamil was more useful during ischemia than 
reperfusion in a canine study [133]. 
 
Clinical evidence for the antiarrhythmic actions of verapamil 
 Verapamil was effective in various cardiac arrhythmias including AF and paroxysmal supraventricular 
tachycardia (PSVT). In a study of 181 patients verapamil treatment (10 mg iv. over 15-30 seconds) significantly 
slowed sinus tachycardia, converted PSVT to SR and reduced VR in patients with AF and AFL very effectively 
[216]. It was also effective in Wolff-Parkinson-White (WPW) syndrome and AV junctional tachycardias but it was 
without effect in VT [217]. In acute myocardial infarction (AMI) patients with supraventricular tachyarrhythmia 
verapamil treatment reduced VR below 100 beats/min in every patients, but conversion to SR was achieved in only 1 
out of 8 patients with AF and 7 out of 8 patients with AFL [218]. In 30 patients with PSVT, conversion to SR was 
achieved in 14 out of 29 patients by low-dose verapamil (0.075 mg/kg body weight), while in 9 out of 15 high-dose 
verapamil (0.15 mg/kg body weight) was required for the conversion [144]. 
Comparisons to β adrenergic receptor blockers showed superiority of verapamil in restoring SR for instance in 
patients with PSVT compared to practolol [219]. Verapamil, unlike atenolol, did not impair exercise tolerance but 
reduced HR in an equally potent manner during the treatment of chronic AF in digitalized patients [220]. There is a 
controversy regarding the superiority of verapamil over digoxin in the treatment of chronic, persistent or permanent 
AF as two studies reported that verapamil either alone or in combination with digoxin is a better choice compared to 
digoxin alone [221], [222] while others reached the conclusion that verapamil is not superior to digoxin treatment 
[223].It seems that verapamil is at least as effective as adenosine in terminating acute episodes of PSVT but it acts 
more rapidly [224]. According to another study one of the first choices for short-term medications of 
supraventricular tachycardia (SVT) is intravenously applied verapamil especially if adenosine is contraindicated or if 
the PSVT terminates rapidly but is immediately recurrent [225]. Two other recent studies concluded that the two 
drugs have similar efficacy in treating PSVT [226], [227]. Adenosine treatment had a higher rate of minor but 
unpleasant adverse effects and a greater risk of relapse, while some patients treated with verapamil may develop 
significant hypotension. Although 80 mg/day verapamil was effective in supraventricular tachyarrhythmias, it did not 
improve either exercise tolerance or cardiac output (CO) in 6 patients with chronic AF [228]. In contrast, in 18 
patients with chronic AF verapamil (240 mg/day) proved to be effective in rate control and exerted a modest 
improvement in exercise tolerance [229]. The atrial ERP was reduced after AF and this reduction was prevented by 
verapamil but not procainamide treatment in adult patients without structural heart disease. During determinations of 
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the post-AF ERP, secondary episodes of AF were unintentionally induced in 12 % of verapamil patients compared to 
90 and 80 % of saline and procainamide patients, respectively [230]. Similarly, atrial ERP shortening induced by 
pacing-induced AF was attenuated after verapamil infusion in 60 patients and the incidence and duration of 
secondary AF was also reduced [231]. 
As mentioned above, verapamil treatment successfully converted SVTs in all 10 patients having WPW syndrome 
[217] or AV reentrant tachycardia [232]. In contrast, verapamil had no effect in WPW syndrome in other studies 
[233], [234]. Verapamil was also effective in intractable ventricular arrhythmias refractory to other treatment in cases 
after cardiopulmonary bypass with normal cardiac function [235] and in severe rheumatic aortic regurgitation 
associated with a dilated, poorly contracting left ventricle [236] as well as in patients with obstructive hypertrophic 
cardiomyopathy [237]. Moreover, a low number of asymptomatic patients with recurrent, sustained VT and a pattern 
of right bundle branch block (RBBB) without organic heart disease VT could be both induced and terminated with 
electrical stimulation. Verapamil terminated VT and prevented the induction of sustained VT [238]. Similarly, in 19 
patients the broad complex tachycardia demonstrating RBBB was converted to SR with verapamil (5 mg intravenous 
boluses of verapamil up to 20 mg or 20 mg verapamil infused over 20 min, titrated to effect with infusion stopped on 
conversion to SR) in 18 patients [239]. In 42 patients with idiopathic VT of left bundle branch block-like 
morphology verapamil treatment (120 mg 3 times daily) reduced VT in approximately 2/3 of the patients but some 
patients exhibit exacerbation of the arrhythmia and verapamil should be avoided [240]. Verapamil (5 to 20 mg 
intravenously over 60 s) effectively terminated paroxysmal sustained monomorphic VT, repetitive non-sustained VT 
or premature ventricular contractions in all 7 patients [241]. On the long run (a mean 5.8 year follow up) in 37 
patients with sustained left VT without apparent structural heart disease verapamil (160 to 320 mg/day) proved to be 
the drug of choice for alleviating symptoms, but non pharmacologic therapy was necessary in 6 patients [242]. 5 mg 
verapamil injection terminated epinephrine induced VPCs and EADs [243] as well as in 8 patients with congenital 
LQTS verapamil eliminated or reduced EADs, suppressed the epinephrine induced VPCs and TdP. It also shortened 
AP and decreased TDR [93]. 6 patients with molecularly defined catecholaminergic polymorphic VT, all carrying a 
cardiac ryanodine receptor (RyR2) mutation and on β adrenergic receptor blocker therapy, received intravenous 
injection of 0.2 mg/kg verapamil and this reduced the number of isolated and successive premature ventricular 
complexes during exercise by 76 % and delayed the appearance of premature ventricular complexes [244]. In a small 
study done on 5 patients with either catecholaminergic polymorphic VT or polymorphic VT addition of verapamil to 
the β adrenergic receptor blockers reduced the number of ventricular ectopic beats during the whole exercise test as 
well as the ratio of ventricular ectopic to sinus beats in one patient [245]. Ischemia-induced arrhythmias were also 
effectively reduced by verapamil. In 31 patients (6 premature ventricular contractions, 19 accelerated idioventricular 
rhythms, 3 VTs, 2 VFs and 1 TdP all with a diagnosis of AMI after mechanical revascularization therapy within 6 h 
of onset of symptoms) intracoronary verapamil (0.25 to 1.0 mg) was effective in rapidly terminating all reperfusion-
induced arrhythmias except for VFs. The intracoronary use of verapamil was without major complications and 
resumptions of arrhythmias [246]. 
Right ventricular outflow tract tachycardia as well as idiopathic verapamil sensitive ventricular tachycardia can both 
be treated with verapamil [247], [248]. In the former case verapamil works by reducing Ca2+ overload [249] while it 
slows down conduction and prevents re-entry in the latter [250]. 
 
D600 (gallopamil) 
Animal studies with D600 
In open-chest anesthetized dogs D600 significantly elevated myocardial blood flow in the non-ischemic 
area, but did not influence blood flow in the ischemic region [251] in contrast to the effect of verapamil, which either 
increased CF to the ischemic area [112] or caused a coronary steal from the ischemic area of the myocardium [128]. 
Ischemia and reperfusion-induced arrhythmias were reduced by D600 in rats [252], dogs [253] and guinea-pigs 
[254]. 
D600, in a dose reducing the contractile force by 50 %, induced a further prolongation of the APD and 
provoked EADs thus it had arrhythmogenic action in a special model of papillary muscles of guinea-pig hearts [129]. 
In Langendorff-perfused rabbit hearts 0.5 mg/l D600 infused during fast VF (dominant frequency, 19.1±1.8 Hz) 
consistently converted fast VF to VT. However, increasing D600, in a higher dose of 2.5 or 5.0 mg/l, converted VT 
to slow VF (11.9±2.3 Hz). D600 in the lower dose inhibited calcium current and mediated antiarrhythmic action. On 
the contrary, higher doses of D600 (evoking INa inhibition) can be arrhythmogenic [130]. 
In cats with left ventricular hypertrophy D600 prolonged sinus CL and AV CT but it did not protect against 
ventricular arrhythmia [255]. 
In open-chest anesthetized dogs with 20 min transient coronary artery occlusion D600 (0.13 mg/kg iv), 
similarly to verapamil (0.25 mg/kg iv) both given 5 min prior the ischemia reduced the epicardial conduction delay 
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of the ischemic area and almost completely suppressed ventricular arrhythmias and VF. Delayed ventricular 
reperfusion arrhythmias were also significantly reduced by both drugs [178]. In dogs 3-7 days after ligation of the 
left anterior descending coronary artery (LAD) D600 and verapamil (0.2-0.5 mg/kg iv) improved the conduction in 
reentrant pathways with abolition of both spontaneous and premature depolarizations evoked reentrant ventricular 
arrhythmias [256]. It seems that lower D600 doses were required to induce antiarrhythmic action in dogs therefore, 
D600 is likely to be more effective in the prevention of cardiac arrhythmias compared to verapamil. On the other 
hand it must be highlighted that D600 was arrhythmogenic at least in guinea-pigs and rabbits under certain 
conditions. 
 
Clinical evidence for the antiarrhythmic actions of D600 
Regarding human data, D600 significantly prolonged CT and the ERP of the AV node just as did verapamil 
[257]. Similarly, in 13 patients with normal SR intravenous administration of D600 increased AV CT. Second degree 
AV block occurred at lower stimulation rates in all patients during atrial stimulation but D600 had no effect on the 
impulse propagation in atrial tissue and within the His-Purkinje system [258]. In 10 AF patients, 100 mg orally given 
D600 decreased the HR for 10 hours. In 5 patients a regularization of the ventricular response was observed without 
bradycardia. Oral administration of 3 times 50 mg D600 daily decreased HR after a treatment period of 1 week to 
about 79 % of control [259]. D600, just as verapamil, evoked bradycardia or SA and AV nodal conduction 
disturbances. Gastrointestinal side effects were stomach problems after D600 and constipation after verapamil [260]. 
In 36 healthy men plasma digoxin concentration was increased by 16 % after 50 mg D600 three times a day and by 
70 % after 80 or 120 mg verapamil [261]. Slow-release formulations of D600 (100 mg twice a day) and verapamil 
(120 mg twice a day) reduced peak HRs recorded during a 6-min walking test to a similar extent in 18 patients with 
permanent AF receiving oral digoxin without organic heart disease. D600 appeared to be less effective at controlling 
VR both at resting and during exercise [262]. 
 
Tiapamil (Ro 11-1781) 
Animal studies with tiapamil 
The antiarrhythmic actions of tiapamil were documented in open-chest pigs with LAD ligation. Tiapamil (6 
mg/kg intravenously) decreased the incidence of VF by 60 %, maintained left ventricular maximal rate of pressure 
rise (dP/dtmax) after ligation and increased blood flow in the peripheral ischemic zone as well as in the peri-ischemic 
and non-ischemic zones [215]. In the same model verapamil in ten times lower dose fully prevented the occurrence 
of VF but left ventricular dP/dtmax was reduced to 50 % without changing blood flow in the peripheral, peri-ischemic, 
or non-ischemic zones. 
Tiapamil reduced the incidence of ventricular ectopic beats (VEBs) both during LAD occlusion and 
reperfusion in a canine model [263]. Furthermore, tiapamil (4.75mg/kg) reduced myocardial infarct size which effect 
was lost with 11.25 mg/kg tiapamil probably due to marked hypotension and varying degrees of heart block [263]. In 
other studies tiapamil possessed again antiarrhythmic actions both during ischemia and reperfusion [264] but in 
others it proved effective against VF only during sympathetic stimulation and myocardial ischemia but not during 
reperfusion [173], [265]. 
In anesthetized open-chest dogs, intravenous tiapamil increased CF and decreased coronary vascular 
resistance, HR, blood pressure (BP) and total peripheral resistance. Tiapamil, in contrast to verapamil, did not 
depress myocardial contractility over a rather wide dose range and was more effective in increasing CF. Tiapamil 
dilated small but not large coronary arteries and raised pO2 relatively more in the subendocardial than in the 
subepicardial layers of the myocardium [266]. 
Compared to verapamil, tiapamil was 33 and 18 times less potent in reducing the contractility of rabbit left 
atrium and right ventricular papillary, respectively [267]. Both tiapamil and verapamil decreased HR and increased 
CF in isolated cat hearts. The vascular selectivity of tiapamil was higher compared to verapamil [161]. 
 
Clinical evidence for the antiarrhythmic actions of tiapamil 
In patients with AFL, AF or PSVT 1 mg/kg intravenous tiapamil produced a marked decrease in VR and 
conversion to SR was achieved in some cases [268]. Tiapamil was also effective in patients with chronic AF. AV CT 
was increased and the frequency of atrial ectopic beats was reduced. Moreover, ectopic beats were reduced by 30-
50 % in 6 out of 20 cases in patients with ventricular premature beats previously not responding to antiarrhythmic 
therapy [269]. In a small study tiapamil effectively restored SR and prevented tachycardias in patients with recurrent 
PSVT except in those with retrograde conduction involving an accessory pathway [270]. Tiapamil was also without 
effect in WPW syndrome patients on anterograde or retrograde RPs of the accessory pathway or on that of the 
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ventricle [271]. Tiapamil (3 times 200 mg per os daily) had positive effects in supraventricular and ventricular 
extrasystoles in 23 patients with extrasystoles of different origin [272]. 
Ischemia related arrhythmias were also effectively reduced by tiapamil as in patients with coronary disease 
and AF it decreased the VR by 54 %, although SR was not restored. The median frequency of VPC decreased just as 
the median ectopic/sinus beat ratio. Hypotension and bradycardia were observed in 5 out of 20 patients [273]. 
Similar results were reported in another article but tiapamil was effective both against supraventricular premature 
complexes and VPCs in contrast to other CCAs [274]. In AMI patients, tiapamil effectively reduced the number of 
premature ventricular contractions [275], supraventricular extra beats [276] and HR to less than 90 beats/min, which 
latter effect was also seen in reoccurring tachyarrhythmias during successive tiapamil administrations [277]. 1 mg/kg 
intravenous tiapamil significantly reduced the number of exercise-induced extrasystoles in patients 3-6 weeks after 
AMI [278]. Tiapamil was effectively used in 32 surgical patients in the treatment of intra- and postoperative cardiac 
arrhythmias such as AF, supraventricular paroxysmal tachycardia and VEBs. Small doses of 0.3-0.5 mg/kg were 
only effective in patients with tachycardic AF. The effective dose was between 1 and 1.5 mg/kg in most other 
arrhythmias [279]. 
 
Anipamil 
Animal studies with anipamil 
There are several animal studies showing the antiarrhythmic action of anipamil in rats [280]-[282] and also 
in pigs [283]. Anipamil had a stronger antiarrhythmic than hypotensive effect compared to verapamil in rats [280]. 
Anipamil pretreatment proved to be protective against LAD ligation induced functional (monitored by ECG signs) 
and biochemical (creatine kinase loss) damage in rats. In reperfusion experiments (0.5 or 1 mg/kg iv. anipamil 
injection 30 min before 5 min ischemia) the incidence of VT and VF was markedly reduced and completely 
prevented by the smaller and the higher anipamil dose, respectively [281]. 2.5 mg/kg anipamil did not produce any 
class I or III effects tested with recording epicardial APs but depressed early plateau phase in rats [282]. 
On the contrary, two studies reported harmful anipamil actions. In pentobarbitone-anesthetized pigs, intravenous 
anipamil exerted arrhythmogenic action as it increased the occurrence of VT and VF. On the contrary, verapamil, in 
a dose which produced similar hemodynamic effects than those of anipamil, reduced the occurrence of VT and VF 
[135], [136]. 8-week-long anipamil treatment aggravated left ventricular dilatation and remodeling, thereby reduced 
survival in rats with healed infarcts and ventricular dysfunction [136]. 
There is no information about the anipamil plasma levels in humans but in rabbits long-term (17 weeks) 
application of daily doses of 1 and 10 mg/kg led to plasma levels of 0.23 and 202 ng/ml (approximately 0.44 and 388 
nM), respectively [284], [285]. There are no human data about the antiarrhythmic actions of anipamil only the 
systolic and diastolic BP reducing [285] and anti ischemic effects of the drug were documented [286]. 
 
TABLE 4. Human studies describing the pro- and antiarrhythmic actions of phenylalkylamines. 
 
DRUG / dose Proarrhythmic 
action Antiarrhythmic action Reference 
Verapamil / 3 x 120 
mg daily for at least 5 
half-lives to load 
exacerbation of 
the arrhythmia 
in idiopathic VT 
of left bundle 
branch block-
like morphology 
 [240] 
Verapamil / 10 mg 
intravenously 
increased ST-
segment 
elevation and 
programmed 
stimulation 
induced 
ventricular 
fibrillation with 
shorter F-F 
intervals in 
Brugada 
syndrome 
 [138] 
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Verapamil / 10 mg 
intravenously over 15-
30 seconds 
 slowed sinus tachycardia, converted PSVT to SR and 
reduced VR in AF and AFL patients 
[216] 
Verapamil / 0.075-
0.15 mg/kg 
 conversion to SR was achieved in 48-60 % of PSVT 
patients 
[144] 
Verapamil / 10 mg 
intravenously 
 successfully converted SVTs in WPW syndrome 
 
or was without effect in WPW syndrome 
[217] 
[233] 
[234] 
Verapamil / 2.5-5 mg 
intravenously 
 was effective in ventricular arrhythmias refractory to 
other treatment in several conditions  
[235] 
[236] 
[237] 
Verapamil / 5 mg 
intravenous boluses 
up to 20 mg 
 broad complex tachycardia demonstrating RBBB was 
converted to SR 
[239] 
Verapamil / 3 x 120 
mg daily for at least 5 
half-lives to load 
 reduced VT in approximately 2/3 of the patients in 
idiopathic VT of left bundle branch block-like 
morphology 
[240] 
Verapamil / 5-20 
mg/min intravenously 
 terminated paroxysmal sustained monomorphic VT, 
repetitive non-sustained VT or premature ventricular 
contractions 
[241] 
Verapamil / 0.2 mg/kg 
intravenously 
 reduced the number of premature ventricular complexes 
in catecholaminergic polymorphic VT carrying a 
cardiac ryanodine receptor mutation 
[244] 
Verapamil / 0.25-1.0 
mg intracoronary 
 terminated all reperfusion-induced arrhythmias except 
for VFs and reduced various ischemia-induced 
arrhythmias 
[246] 
Verapamil / up to 20 
mg in 1 mg/min 
increments, 
intravenously, titrated 
to effect 
 in supraventricular tachyarrhythmia VR was reduced 
below 100 beats/min in patients within 72 hours with of 
AMI, conversion to SR was done in most patients with 
AFL 
[218] 
Verapamil / 240 mg 
SR tablet daily 
 right ventricular outflow tract tachycardia was 
terminated 
[247] 
D600 / 100 mg per os  decreased the HR for 10 hours in AF [259] 
Tiapamil / 1 mg/kg 
intravenously   
 reduced VR and rhythm was converted to SR in some 
cases in AFL, AF or PSVT patients 
[268] 
Tiapamil / 1 mg/kg or 
50 µg/kg/min for 4 h 
intravenously 
 ectopic beats were reduced in patients with atrial and 
ventricular premature beats, AV CT was increased in 
chronic AF 
[269] 
Tiapamil / a bolus of 2 
mg/kg intravenously, 
1x 1.2-1.5 g daily 
 restored SR and prevented tachycardias in patients with 
recurrent PSVT having no accessory pathway 
[270] 
Tiapamil / 3 x 200 mg 
daily per os 
 positive effects in supraventricular and ventricular 
extrasystoles 
[272] 
Tiapamil / 1 mg/kg 
then 50 µg/kg/min for 
4 h intravenously 
 reduced ischemia related arrhythmias, decreased the VR 
in patients with AF 
[273] 
Tiapamil / 1 mg/kg 
then 25 µg/kg/min 
intravenously 
 reduced the number of premature ventricular 
contractions, supraventricular extra beats, HR to less 
than 90 beats/min and exercise-induced extrasystoles in 
patients with or after AMI  
[275] 
[276] 
[277] 
[278] 
Tiapamil / 1-1.5 
mg/kg intravenously   
 reduced intra- and postoperative cardiac arrhythmias 
such as AF, supraventricular paroxysmal tachycardia 
and in VEBs 
[279] 
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9.2. Benzothiazepines 
 
Diltiazem 
Animal studies with diltiazem 
Antiarrhythmic actions of diltiazem on both ischemia- and reperfusion-induced arrhythmias were described 
in rats [287], [288]. The antiarrhythmic actions were attributed to its negative chronotropic [287] or its energy-
sparing properties [288]. The protective effects of diltiazem against VF were observed in canine ischemia models 
[173], [174], [178] but the drug proved to be ineffective in preventing tachycardia induced atrial remodeling 
compared to placebo [289]. 
The cardiac selectivity of diltiazem was described in rabbit [28], in dog [176] and also in human preparation [27]. 
The EC50 values for vasorelaxation and negative inotropy were 277 nM and 39 µM, respectively, in rabbit tissues 
[28] while 0.69 and 7.2 µM in human coronary artery and right ventricular trabeculae [27]. The smallest cardiac 
selectivity was seen in canine tissue as blood flow rate was doubled by 21 µg while 110 µg caused a 50 % reduction 
in force of contraction [176]. 
 
Clinical evidence for the antiarrhythmic actions of diltiazem 
Diltiazem and digoxin had additive depressant effects on SA and AV node function (increased sinus CL, AH CT, 
AV node functional and effective RPs) as well as on atrial function (reduced atrial RP) without significant adverse 
effects in patients without conduction disorders [290]. 
Intravenous diltiazem effectively and safely reduced HR in patients with AF or AFL. Hypotension was the 
most common side effect, occurring in 13 % of patients. Symptomatic hypotension was present in 3.6 % of patients, 
and responded to normal saline solution in all cases [291]. Similar beneficial actions were seen in another, placebo 
controlled study involving 113 AF or AFL patients without severe HF [292] as well as in 37 AF or AFL patients 
with moderate to severe congestive HF [293]. Intravenous diltiazem proved to be more effective and faster acting (in 
5 min) than intravenous digoxin (acting only in 3 hours) or the combination of the two drugs in AF and AFL patients 
[294]. Moreover, in a study involving 180 patients with rapid AF, low-dose diltiazem (≤ 0.2 mg/kg as a starting 
intravenous bolus) proved to be as effective as the standard dose of 0.25 mg/kg (according to the 2006 guidelines 
developed by the American College of Cardiology/American Heart Association/European Society of Cardiology for 
the management of patients with AF) in adequate rate control but the complication of hypotension was seen 
significantly less frequently 18 vs. 35 % in low and standard doses, respectively [295]. 
Oral diltiazem treatment also effectively lowered VR in patients with AF [296] and also reduced the maximal and 
submaximal HRs during exercise without affecting oxygen uptake, minute ventilation, respiratory exchange ratio or 
BP [297]. The effects of diltiazem on exercise tolerance are controversial in chronic AF as one study found a modest 
improvement similarly to that observed with verapamil [229] while another found no benefit in terms of improving 
either exercise tolerance or CO with either diltiazem or verapamil [228]. When compared to other drugs in 
controlling the VR at rest and during exercise in patients with chronic AF, diltiazem (240 mg daily) proved to be 
least effective compared to atenolol treatment but it more effectively reduced HR during exercise compared to 
digoxin [298]. In chronic AF patients 240 mg/day diltiazem combined with digoxin is an effective and safe regimen 
and enhances digoxin-mediated control of HR both at rest and during exercise [299], [300]. The same combined 
treatment alleviated the symptoms in 69 % of the patients without changing the digoxin serum level [300] and was 
superior for control of 24-hour mean HR as compared to each drug used separately [301]. Slow-release formulation 
of diltiazem (120 mg twice a day) similarly to D600 (100 mg twice a day) and verapamil (120 mg twice a day) 
reduced peak HRs recorded during a 6-min walking test to similar extent in 18 permanent AF patients without 
organic heart disease but receiving oral digoxin [262]. 
Intravenous diltiazem effectively converted VT to SR (in 87 % of SVT patients) or slowed HR to 100 beats/min or 
even below (in 82 % of patients) [302]. Similar results were found in patients with inducible sustained SVT but 
diltiazem had no effect on the electrophysiological properties of accessory AV connections and was safe and very 
effective for acute tachycardia termination when the AV node was part of the reentrant circuit [303]. In another study 
involving 87 patients (25 with AV nodal reentry tachycardia, 60 with AV reentry associated with an accessory AV 
connection, and 2 with AT) the time to conversion was 3 minutes in diltiazem responding patients and the most 
frequent adverse response to diltiazem was hypotension in 11 % of patients [304]. 
The incidence of postoperative AF in 60 patients, monitored continuously for 8 days after coronary bypass grafting 
with extracorporal circulation, was lower by diltiazem (10 % of patients) compared to the standard prophylactic 
regimen of an oral beta blocker (23.3 % of patients) [305]. CCAs, especially diltiazem were found to be beneficial 
after non-cardiac surgery in reducing the relative risk of myocardial ischemia and SVT [306]. Moreover, diltiazem, 
similarly to verapamil, effectively converted broad complex tachycardia demonstrating RBBB to SR [239]. 
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Siratiazem (LR-A113) 
Animal studies with siratiazem 
Siratiazem evoked an antiarrhythmic action in a rat ischemia-reperfusion model as 2 mg/kg siratiazem 
reduced the incidence of VF on reperfusion. It also caused a reduction of HR and MAP [115]. The antiarrhythmic 
effect of siratiazem was similar to diltiazem, but less potent compared to that of verapamil in rats and guinea-pigs 
when studied with calcium, aconitine- and ouabain-induced arrhythmias [307]. 
 
Clentiazem (TA-3090) 
Animal studies with clentiazem 
Clentiazem treatment did not change transmural collateral flow measured 15 min after occlusion and the 
area at risk in an ischemic canine model. Infarct size was reduced by clentiazem only in those animals having a 
collateral flow greater than 0.02 ml/min/g, but not in those with lesser collateral flow [308]. 
In a hamster chronic HF model, clentiazem reduced inotropy with an EC50 of 734 nM, similarly to that observed in 
normal hearts (677 nM). The coronary circulation was enhanced by clentiazem in both normal and failing hearts, 
although less pronounced action was detected in the latter (EC50 values were 56 and 15 nM, respectively) [309]. 
 
Clinical evidence for the antiarrhythmic actions of clentiazem 
In 11 patients with PSVT, clentiazem (0.1 mg/kg intravenously for 3 minutes) terminated programmed 
electrical stimulation-induced SVT at high right atrium in 9 out of 11 cases, while diltiazem (0.2 mg/kg) was more 
effective as it terminated 4 out of 4 cases [310]. In patients with stable angina, as low as 40 mg/day clentiazem 
reduced the HR and increased exercise duration after 4 hours of medication. After 12 hours only 80 and 120 mg/day 
doses had antianginal action. The most frequently reported treatment-related adverse events with clentiazem were 
asthenia, headache (both 7.9 %), first-degree AV block and dizziness (both 4.4 %) [311]. 
 
S-2150 
Animal studies with S-2150 
S-2150 (Fig. 3.) applied to anesthetized rats (30-60 mg/kg per os or 5 mg/kg intravenous pretreatment) 
reduced the myocardial infarct size just as diltiazem (5 mg/kg) and verapamil (3 mg/kg) [68]. The incidence of VT 
and fibrillation, induced by 4 min occlusion followed by reperfusion of the coronary artery, was reduced almost to 
zero by 60 mg/kg S-2150. Moreover, S-2150 also decreased cardiac mechanical function and increased CF [68]. 
Compared to diltiazem, S-2150 was less cardiodepressive but exerted stronger vasodilatation [68]. Similarly, in 
anesthetized open-chest dogs, S-2150 decreased myocardial work to a greater extent compared to diltiazem while 
caused a comparable hypotensive effect. S-2150 more promptly improved the local myocardial stunning caused by 
ischemia and reperfusion and unlike with diltiazem, this effect did not accompany the energy-sparing action in 
ischemic/reperfused myocardium. These results suggest that S-2150 is a favorable hypotensive agent for 
hypertensive patients with ischemic heart disease [312]. 
 
TABLE 5. Human studies describing the pro- and antiarrhythmic actions of benzothiazepines. 
 
DRUG / dose Proarrhythmic action Antiarrhythmic action Reference 
Diltiazem / 50 mg infused 
over 20 min, titrated to 
effect 
 broad complex tachycardia demonstrating 
RBBB was converted to SR 
[239] 
Diltiazem / intravenously 
0.25 or 0.35 mg/kg/ over 2 
minutes 
 reduced HR in patients with AF or AFL 
regardless the presence of absence of 
congestive HF 
[292] 
[293] 
Diltiazem / once 120 mg 
or 3x80 mg daily per os 
 lowered VR in patients with AF [296]  
Diltiazem / 4x60 mg per os  reduced the maximal and submaximal HRs 
during exercise 
[297] 
Diltiazem / bolus of either 
150 or 300 µg/kg over 2 
minutes intravenously 
 converted VT to SR, reduced HR to 100 
beats/min 
[302] 
Diltiazem / continuous 
infusion of for 24 h 
(minimum dose, 0.l 
 reduced the incidence of AF after coronary 
bypass grafting 
[305] 
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mg/kg/h) 
Diltiazem / 0.2 mg/kg 
intravenously for 3 
minutes 
 terminated programmed electrical 
stimulation induced SVT at high right 
atrium 
[310] 
Clentiazem (TA-3090) / 
0.1 mg/kg intravenously 
for 3 minutes 
 terminated programmed electrical 
stimulation induced SVT at high right 
atrium 
[310] 
Clentiazem / 80 and 120 
mg/day 
 antianginal action in patients with stable 
angina 
[311] 
Clentiazem / 80 and 120 
mg/day 
induced first-degree 
AV block as a side-
effect in patients with 
stable angina 
 [311] 
 
9.3. Other CCAs 
 
Semotiadil (SD-3211) 
Animal studies with semotiadil 
The tau-on of negative dromotropic action was shorter for diltiazem and longer with verapamil compared to 
that of semotiadil in isolated guinea-pig hearts. During AFL semotiadil has a verapamil type of action on ventricular 
CL, whereas the disadvantageous prolongation of maximal ventricular CL as well as the dispersion of ventricular CL 
with semotiadil was only about half of those found with verapamil [172]. 
Comparing the vascular over cardiac selectivity of semotiadil with that of diltiazem and verapamil semotiadil was 
more vasoselective than the other two in guinea-pigs [6]; than diltiazem in isolated perfused rat hearts [313] and in 
anesthetized open-chest dogs [314]. 
Semotiadil produced antiarrhythmic actions in anesthetized rats as the number of total ventricular premature 
beats occurring during ischemia as well as the incidence of reperfusion-induced VF were reduced very effectively by 
the drug (EC50 values of 11 and 372 nM, respectively) [315]. On the contrary, semotiadil (1 mg/kg) exerted no 
antiarrhythmic action in a canine model [316]. 
 
Levosemotiadil (SD-3212) 
Animal studies with levosemotiadil 
There are much more data about the antiarrhythmic actions of levosemotiadil compared to semotiadil. In 
anesthetized rats, levosemotiadil reduced the number of total ventricular premature beats during the ligation period 
with an EC50 of 39 nM (4 times less potently than semotiadil) and reduced the incidence of reperfusion-induced VF 
with an EC50 of 32 nM (11 times more effectively than semotiadil) [315]. Levosemotiadil (3 mg/kg) had more potent 
antiarrhythmic properties compared to semotiadil (1 mg/kg) as it reduced the ratio of ectopic beats in a canine model 
[316]. Levosemotiadil suppressed adrenaline-induced arrhythmia in dogs and showed some antiarrhythmic effect on 
arrhythmias induced by either digitalis or 48 hour long coronary ligation [317]. Levosemotiadil (in 1.9 mg/kg mean 
dose and a plasma level of 187 ng/ml, approx. 350 nM) terminated AFL after significant increase in AFL CL in a 
canine model [117]. Levosemotiadil (30 mg/kg/daily per os for 7 days) prevented VF in 64 % of conscious dogs at 
high risk for VF. HR responses to myocardial ischemia and to graded doses of isoproterenol were blunted by 
levosemotiadil, which had approximately half the β-blocking activity of propranolol. The combination of INa and ICa,L 
channel and partial β-adrenergic blockades was equally effective in preventing VF as propranolol (73 %) [318]. Due 
to these effects the antiarrhythmic properties of levosemotiadil in ventricular arrhythmias are more pronounced 
compared to semotiadil. 
 
Fantofarone (SR 33557) 
Animal studies with fantofarone 
Contractile responses were more potently antagonized by fantofarone (Fig. 4.) compared to verapamil and 
diltiazem aortic strips and portal veins of the rat [319]. The negative inotropic action of fantofarone was smaller and 
bigger than that of verapamil and diltiazem, respectively, on rabbit left atria. Fantofarone was particularly selective 
for vascular smooth muscle and devoid of any potent negative inotropic actions [319]. 
The negative chronotropic effects were greater with fantofarone than with verapamil or diltiazem on spontaneous 
right atrial rate of rabbit atrium [319]. 
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Direct antiarrhythmic action of fantofarone is not documented but, in a dose of 100 mg/kg, it decreased the 
calcium content in rat hearts where calcium overload was induced by vitamin D3 [95]. Fantofarone, at concentrations 
which cause minimal alterations to normal function, can significantly improve functional recovery following an 
ischemic insult in the rat heart [320]. In isovolumic perfused rat heart, 20 min pretreatment of 1 µM fantofarone 
significantly improved the recovery of mechanical performance, metabolic activity and cytosolic pH after 18 min of 
ischemia. Fantofarone treatment was even more beneficial during the reperfusion period. Higher recoveries of left 
ventricular pressure and rate pressure product, low end diastolic pressure, significant and complete recovery of ATP 
and phosphocreatine pool and a fast return of cytosolic pH to normal value were detected [321]. In anesthetized dogs 
25 µg/kg intravenous fantofarone induced a decrease in myocardial oxygen consumption during periods of normal 
but not of elevated HR. In double dose, a decrease in myocardial oxygen consumption was maintained during 
pacing-induced elevated HR [108]. 
 
Human data on hemodynamic effects of fantofarone 
In 6 healthy volunteers a single oral administration of 100 and 300 mg fantofarone resulted in peak plasma 
concentrations of its active metabolite SR 33671 of 16 and 63 ng/ml, respectively [322]. 
Fantofarone was examined on human volunteers where 100 and 300 mg per os did not change systemic 
hemodynamics, although arterial pressure and CO tended to decrease slightly after 300 mg [323]. In contrast, at the 
regional level, fantofarone produced strong vasodilatation of arterioles and, as a consequence, significantly increased 
brachial and carotid blood flow. The blood flow was preferentially increased in the brachial arterioles resulting in a 
redistribution of CO towards the musculocutaneous tissues. Fantofarone caused a marked and long-lasting decrease 
in HR, but it did not affect the auriculo-ventricular CT [323]. These effects were largely mediated by its active 
metabolite SR 33671 [322]. The effects of fantofarone (5 mg iv. in 10 min) were tested in both before and during 
right atrial pacing (100 beats/min) in 9 patients with coronary artery disease and normal systolic left ventricular 
function. Without atrial pacing, fantofarone decreased HR, MAP, left ventricular dP/dtmax and rate-pressure product; 
increased stroke volume index but had no effect on cardiac index, filling pressures or systemic vascular resistance. 
During the pacing phase, none of the hemodynamic parameters differed from baseline including especially dP/dtmax. 
Fantofarone has negative chronotropic action but shows no direct negative inotropic effect in patients with normal 
systolic left ventricular function [324]. Fantofarone, in doses of 100-150 mg twice daily, was effective and safe in the 
treatment of patients with chronic, stable angina pectoris as the drug prolonged exercise time without any effect on 
systolic BP both at rest and during exercise. Sinus bradycardia occurred in approximately 10 % of the patients [325]. 
 
SR 33805 
Animal studies with SR 33805 
In isolated rabbit atrial preparations, SR 33805 exerted weaker negative chronotropic and inotropic response 
(EC50 values of 6 and 12 µM, respectively) compared to fantofarone, verapamil and diltiazem. In superfused rat 
aortic strips and in femoral, renal and basilar arteries, SR 33805 reduced potassium-induced contractile responses 
(IC50 approximately 40 nM) to a similar extent to those seen with fantofarone, verapamil and diltiazem. Moreover, 
unlike other CCAs, SR 33805 also reduced serotonin-induced contractions (IC50 approximately 250 nM). SR 33805 
is a potent CCA highly selective for vascular smooth muscle and devoid of any potent negative inotropic actions 
[79]. 
Beneficial actions of SR 33805 include the reduction of calcium overload induced with vitamin D3 and its 
deleterious consequences (lesions appearing in the tissue adjacent to the arteries) of rat hearts (per os 30 mg/kg) [95], 
the restoration of myocardial infarction-altered cell shortening without affecting the calcium transient amplitude in 
cardiomyocytes isolated from rat with end-stage HF and the improvement of end-systolic strain and fractional 
shortening of hearts with myocardial infarction in vivo (a single intra-peritoneal bolus of 20 mg/kg) [189]. 
SR 33805 was more effective in reducing calcium overload compared to fantofarone and verapamil [95]. 
 
BRL-32872 
Animal studies with BRL-32872 
Proarrhythmic actions of BRL-32872 were rare as in guinea-pig papillary muscle 1 µM produced EADs in 
only one experiment (out of 35) which was suppressed at 3 µM [41] and in canine Purkinje fibers EADs were never 
detected [190]. 
BRL-32872 can be very useful in antiarrhythmic treatment due to the lack of reverse frequency-dependent effect on 
APD and the relative absence of EADs. The ability of BRL-32872 to antagonize EADs produced by E-4031 in 
guinea-pig papillary muscle [41] or by clofilium in canine Purkinje fibers [190] adds to its antiarrhythmic potential. 
Moreover, BRL-32872 limited the increase in APD heterogeneity between ventricular muscle and Purkinje 
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preparations which might also represent the basis for its antiarrhythmic action [190]. 0.1-1 µM BRL-32872, similarly 
to flecainide and dofetilide, significantly lengthened CL of AF, prolonged ERPs and reduced AF inducibility in a 
model of acute stretch-related AF in isolated rabbit hearts, [326][327]. 
In vivo experiments also support the antiarrhythmic actions of BRL-32872. The incidence of VF was reduced to 13 
and 0 % by 0.3 and 1.0 mg/kg intravenously given BRL-32872, respectively, compared to 66 % observed without the 
drug in minipigs with 20-min LAD occlusion. The antifibrillatory effects of BRL-32872 and dofetilide were 
associated with a prolongation of QT interval on ECG. The protective effect of BRL-32872 was greater compared to 
dofetilide during early reperfusion and this was most likely due to its calcium channel blocking activity [327]. This 
was confirmed as BRL-32872 was more potent than E-4031 in reducing the severity of arrhythmias whereas 
verapamil was without effect in a canine model. Combination of E-4031 with verapamil provided a similar degree of 
protection to that observed with BRL-32872 [328]. Similarly, in anesthetized rabbits sensitized to develop TdP, 
BRL-32872 (10 µg/kg/min) prolonged QT interval without inducing TdP. Classical class III antiarrhythmic agents 
including E-4031 and dofetilide increased QT interval and induced TdP in 50-90 % of the rabbits. The addition of 
verapamil reduced the incidence of TdP induced by E-4031 [328]. 
 
KT-362 
Animal studies with KT-362 
Antiarrhythmic actions of KT-362 were detected in anesthetized dogs subjected to a 15-min or 90-min LAD 
occlusion followed by 3 hours of reperfusion. KT-362 treatment (0.3 mg/kg/min intravenously started 10-15 min 
before and continued throughout the occlusion) reduced the incidence of reperfusion-induced VF and markedly 
improved myocardial segment shortening of the ischemic-reperfused region. Moreover, myocardial infarct size was 
reduced by KT-362 [329][330]. 
KT-362 (10 mg/kg intravenously) suppressed coronary ligation arrhythmia and induced a transient hypotension in a 
canine model. Oral administration of 70-100 mg/kg was also effective on 24 hr coronary ligation arrhythmia but it 
produced no prominent hypotension. KT-362 was more effective against digitalis- and adrenaline-induced 
arrhythmias as the required doses were only 3 and 1 mg/kg, respectively [331]. 
There are several studies where a comparison of KT-362 with other CCAs is made. Verapamil, but not KT-362, 
significantly increased CF in guinea-pig hearts. EC50 values for negative inotropy, chronotropy and dromotropy were 
about 25, 3 and 3 times lower for verapamil compared to those with KT-362 [42]. Verapamil was again more potent 
than KT-362 in anesthetized dogs as prolongation of PQ interval on the electrocardiogram was observed with 0.1 
mg/kg verapamil but KT-362 even at 10 mg/kg evoked no negative dromotropic action [332][333]. In anesthetized 
ischemic dogs KT-362 (0.3 mg/kg/min intravenously started 10-15 min before and continued throughout the 
occlusion) but not diltiazem (15 and 30 µg/kg/min) produced a significant decrease in HR and dP/dtmax [333]. In 
rabbit aorta in the absence of extracellular calcium, responses to norepinephrine and methoxamine were inhibited by 
KT-362 (1-100 µM) but not by verapamil or diltiazem (10 µM each) [191]. 
 
Mibefradil (RO 40-5967) 
Animal studies with mibefradil 
Mibefradil evoked antiarrhythmic action in Langendorff-perfused rat hearts. VF occurring during 30 min 
regional ischemia was abolished by 600 nM mibefradil but reperfusion-induced VF incidence was not changed 
[334]. Similar results were found in open chest pigs where the low (clinically relevant) dose of mibefradil prevented 
the fall of the VF threshold, without depressing contractility during the ischemic period. The double mibefradil dose 
was antiarrhythmic during ischemia and during reperfusion, at the cost of depressed contractile activity [335], [336]. 
In dogs with healed infarctions, mibefradil (125-1000 µg/kg) prevented programmed electrical stimulation evoked 
arrhythmias during ischemia [174]. Rapid atrial pacing (400 bpm) for 7 days decreased atrial ERP and increased 
ERP heterogeneity, AF duration, and AF inducibility by single extrastimuli in dogs. Mibefradil treatment (100 
mg/day throughout the 7 days of pacing but not that of acute administration) strongly attenuated tachypacing induced 
changes in ERP, AF duration and inducibility [289][336]. 
The cardiac selectivity of mibefradil was described in many species. EC50 of negative inotropy was 12 times higher 
than the one which doubled CF in guinea-pig whole hearts [49]. Mibefradil increased CF with an EC50 of 54 nM and 
reduced contractility of myocardium and aorta with EC50 values of 14 µM and 275 nM, respectively [337]. In human 
small arteries, the potassium contractures and isoprenaline-stimulated right atrial contractions were inhibited with 
IC50 values of 603 nM and 24.5 µM, respectively, indicating a high (41) vascular selectivity of mibefradil [8]. 300 
and 600 nM mibefradil showed a marked vascular selectivity in Langendorff-perfused rat hearts [334]. In open chest 
pigs, the low (clinically relevant) dose of mibefradil increased left ventricular blood flow without depressing 
contractility [335][336]. 
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Comparing the extent of the effects of mibefradil with other CCAs in guinea-pig ventricular cells, the negative 
inotropic action of mibefradil was more potent than that of diltiazem (EC50 values of 6.3 and 31.6 µM, respectively) 
[338]. On the contrary, in conscious normotensive rats, intravenous mibefradil possessed the smallest negative 
inotropic action compared to both verapamil and diltiazem [339]. In isovolumically beating perfused control and 
early phase HF rabbit hearts, mibefradil did not exert negative inotropic action up to 10 µM whereas both verapamil 
and diltiazem had a more potent effect in reducing contractility. Moreover, the negative inotropic actions of 
verapamil and diltiazem, but not that of mibefradil, were larger in HF than in control hearts [340]. In dogs with 
chronic HF intravenous mibefradil, but not diltiazem, caused significant improvement in contractility [341]. 
Verapamil was more potent in reducing the diastolic relaxation and developed pressure in Langendorff-perfused rat 
hearts [334]. 
 
Clinical evidence for the antiarrhythmic actions of mibefradil 
 In mild to moderate hypertension patients, after 4 weeks of per os mibefradil treatment the BP reduction as 
well as the prolongation of PQ interval was proportional with the measured plasma levels and only the highest dose 
(150 mg daily) was associated with cardiac complications related to AV block and bradycardia [193]. Acute effects 
of intravenous mibefradil (15 mg in 15 min followed by 25 mg in 60 min or 35 mg in 15 min followed by 45 mg in 
60 min) tested on 71 patients included a reduction in sinus node recovery time, an increase of AH interval in the 
higher dose, and an increase of AV nodal refractoriness with both doses [342]. Sinus node automaticity was 
suppressed and HR was lowered comparatively more than its negative dromotropic effect on the AV node by a single 
dose of 100 mg mibefradil after 90 minutes [343]. In patients with higher than 40 % EF, the plasma level of 
800 ng/ml achieved by intravenous administration, which is equivalent with an oral dose of 100 mg mibefradil, 
reduced MAP, total peripheral resistance and left ventricular end diastolic pressure; had no effect on HR but 
increased EF (from 52 to 58 %). In patients with low EF (less than 40 %) the same dose of mibefradil reduced HR 
but exerted a negative inotropic action. On the contrary, the 50 % reduced dose not only reduced HR but also 
improved EF. It seems therefore, that high plasma concentrations of mibefradil might produce myocardial depression 
in patients with HF [344]. In 309 patients with coronary artery disease, stable angina pectoris and positive exercise 
tests, mibefradil (in 100 and 150 mg/day doses) proved to be more effective as an anti ischemic drug compared to 
both amlodipine (10 mg/day) and placebo [345]. The Mach-1 study, done on 2590 congestive HF patients with a 
follow up of up to 3 years, showed that adjunct mibefradil treatment (50-mg/day for 1 month followed by 
100 mg/day for up to 3 years) did not have a beneficial effect on total mortality and cardiovascular 
morbidity/mortality. Moreover, mibefradil increased risk of mortality by 14 % in the first 3 months which was not 
significant. Patients co-medicated with mibefradil and antiarrhythmics (class I or III), including amiodarone, had a 
significantly increased risk of death [346]. Mibefradil caused TdP [347] and sinus arrest [348] and interfered with the 
metabolism of many drugs as it is degraded by the cytochrome P450 pathway [349]. Due to the disappointing results 
of the Mach-1 study and the abovementioned severe side effects mibefradil was withdrawn from the market [350]. 
This happened only after the limited selectivity of the drug on T-type calcium channels has been discovered. 
 
Monatepil (AJ-2615) 
Animal studies with monatepil 
Monatepil (Fig. 5.) was shown to possess α1-adrenoceptor blocking activity [351], which could contribute 
to its hypotensive effect by 20-35 % [352]. 
Monatepil exerted antiarrhythmic action in rats as ventricular arrhythmias induced by adrenaline, as well as 
AT induced by aconitine was suppressed by intravenously applied monatepil (0.1-3.0 mg/kg) [353]. The antianginal 
effect of 0.1 mg/kg intravenous monatepil was more potent than that of diltiazem (0.3 mg/kg) in anesthetized rats 
[353]. 
Similarly, monatepil was more effective in inhibiting the potassium-induced contractile response and calcium influx 
in rat aorta (3 and 10 times more potent than verapamil and diltiazem, respectively) [351]. The antianginal effect of 
0.1 mg/kg intravenous monatepil was more potent than that of diltiazem (0.3 mg/kg) in anesthetized rats [353]. The 
effects of monatepil on cardiac function and myocardial oxygen supply and demand were comparable with those of 
diltiazem, but the negative chronotropic and negative dromotropic effects of monatepil were less potent, therefore 
monatepil is a safer drug in the treatment of hypertension than diltiazem [354]. Indeed, in various hypertensive 
models of dogs and rats monatepil evoked an antihypertensive effect which developed more slowly and lasted longer 
compared to diltiazem [355]. Moreover, monatepil exerted comparable or more potent antiarrhythmic action than 
diltiazem or verapamil in rats but its proarrhythmic activity was less potent than that of the other two [353]. 
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In a human study monatepil reduced both systolic and diastolic pressure without affecting the HR. In this regard it 
was similar to nitrendipine but monatepil had additional favorable effects on carbohydrate and lipid metabolism 
[356]. 
 
Human data on hemodynamic effects of monatepil 
 In patients with essential hypertension monatepil decreased BP to similar extent when applied alone or 
combined with ACE inhibitors. When monatepil was combined with β-blockers, the rate of responders and the 
reduction in both systolic and diastolic BP was lower compared to the other two groups [357]. 
 
Bepridil (CERM-1978) 
Animal studies with bepridil 
The antiarrhythmic actions of bepridil were described in ouabain-intoxicated canine Purkinje fibers [358], 
in rats [359], in anesthetized guinea-pigs [360] and also in isolated rabbit hearts [361]. 
Intravenous bepridil increased right atrial ERP and prevented VT in 33 and 50 % of chronically infarcted dogs in 5 
and 10 mg/kg, respectively [362]. 5 mg/kg bepridil reduced myocardial oxygen consumption, HR, the number of 
VEBs and also abolished VF [109]. Similarly, in anesthetized rats, the number of total ventricular premature beats 
during coronary ligation and the incidence of reperfusion-induced VF were reduced with EC50 values of 229 and 676 
nM, respectively [315]. Bepridil suppressed the aconitine-induced dysrhythmias in anesthetized cats (in 5 mg/kg 
given intravenously) [363] but not in mice (in 20-100 mg/kg given intraperitoneally) [359]. Bepridil proved to be 
beneficial in AF in dogs as 4 mg/kg intravenous bepridil increased sinus CL, prevented the development of AF and 
reduced the shortening of monophasic APD90 probably due to the inhibition of IKAch [120]. Another study showed 
that bepridil (10 mg/kg/day) reversed the electrophysiological consequences of atrial remodeling (shortening of atrial 
ERP) to some extent. L-type calcium channel downregulation (at least on mRNA level) and ERP was also reversed 
and the latter positively correlated with α1C mRNA expression [364]. Moreover, 1.8 mg/kg bepridil was protective 
against programmed electrical stimulation-induced VT. A correlation was found between the effective 
antiarrhythmic dose of bepridil and percentage changes in both the ERP for the first extrastimulus and QTc, 
suggesting that a parallel and homogeneous prolongation in repolarization and refractoriness is essential for the 
antiarrhythmic effect of bepridil [99]. In 15 dogs, 4-8 days after myocardial infarction, 5 mg/kg intravenous bepridil 
prevented or significantly slowed sustained VT in 11/12 experiments. Bepridil prolonged the ERP of infarcted 
myocardium to a greater extent (15 %) compared to normal tissue (9 %) [365]. 
On the contrary, bepridil in the same dose (5 mg/kg) administered to dogs during coronary occlusion proved to be 
arrhythmogenic but it must be noted that bepridil administration during the reperfusion period absolutely prevented 
VF [133]. In canine Purkinje fibers, 1-10 µM bepridil evoked EAD at long CL but the triggered activity was rare 
[131]. Finally in a canine model no antiarrhythmic action of bepridil (1-6 mg/kg) was found [316]. 
Comparing the extent of the effects of bepridil to other CCAs it seems that bepridil is not the most potent CCA. 
Bepridil exerted less potent negative dromotropic action compared to verapamil [116] and also to diltiazem [177]. 
The negative inotropic action compared to both verapamil and diltiazem [175][366] was also weaker just as its 
negative chronotropic action compared to the two drugs [175], as well as its antiarrhythmic action compared to both 
semotiadil and levosemotiadil [315]. Similarly, the action of bepridil was at least 10 times less potent on HR and the 
AV nodal conduction compared to verapamil in Langendorff-perfused rabbit hearts [367]. The increase of CF by 
bepridil was smaller than that seen with diltiazem but comparable to that of verapamil [366]. 
In rabbit aorta SMCs only bepridil reduced both the potassium- and norepinephrine-induced contractions whereas 
diltiazem and verapamil inhibited only the depolarization-induced ones, and bepridil was one of the most vascular 
selective CCAs [366]. Unlike verapamil and diltiazem, which had no effect on ventricular level, bepridil caused a 
small increase in QRS and a bigger increase in RP and QTc [177]. 
 
Clinical evidence for the antiarrhythmic actions of bepridil 
Many human studies described the antiarrhythmic properties of bepridil. In 20 patients bepridil appeared 
beneficial in suppressing AFL, atrial and ventricular extrasystoles [368]. 
Regarding ventricular arrhythmias bepridil was effective in non-responding VT in the dose of a single 800 mg 
followed by 500-600 mg as it prevented VT initiation in 66 % of the cases and caused side effects (paralytic ileus) in 
only 1 patient. Three patients remained symptom-free over a follow-up of 4 to 13 months [369]. Bepridil prevented 
VT induction in 47 % of patients with symptomatic VT [370]. AV reentrant tachycardia was terminated in 30 % of 
the 20 patients by 2 mg/kg intravenous bepridil [232]. In the presence of 3 mg/kg bepridil, VT was still inducible in 
19 patients out of 21 versus 20 out of 21 in the absence of bepridil indicating its limited potency to suppress VT 
[371]. On the contrary, intravenous bepridil (2 mg/kg) prevented the induction of sustained VT in 21 % of 38 
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patients. 900 mg/day bepridil was more effective as it prevented the induction of sustained VT in 50 % of patients. 
The response to intravenous bepridil did not predict the response to oral bepridil. The response to any form of 
bepridil treatment was not related to the plasma level of bepridil but was rather related to a higher left ventricular EF. 
In conclusion, that study suggested that oral bepridil at the dose of 600 mg/day may be useful in patients with 
recurrent VT [372]. During a mean follow-up of 52±44 months, bepridil (mean dose of 156 mg/day) completely 
suppressed ventricular tachyarrhythmias in 38 % of the patients and decreased the frequency of ventricular 
tachyarrhythmia recurrences by more than 75 % in 30 % of the patients [373]. In a study on 8 men with idiopathic 
VF, bepridil (200 mg/day) effectively reduced the frequency of VF episodes in association with prolongation of QT 
intervals at slower HRs [374]. In 21 patients with frequent VPCs, 900 mg bepridil for 2 days as loading followed by 
12 days of 400 mg daily, reduced VPC frequency more than 70 % in 48 % of the patients. In 50 % of the patients at 
least a 95 % reduction in frequency of non-sustained VT was observed. Gastrointestinal and central nervous system 
side effects were considered to be mild and occurred in 62 % of the patients. Bepridil had moderate antiarrhythmic 
efficacy in patients with ventricular arrhythmias [375]. 
AF was usually more sensitive to bepridil and a correlation was found between the efficacy of bepridil in AF and its 
plasma concentration measured just before the intake of the next oral dose. The target value to obtain clinical benefit 
was approximately 300 ng/ml [376]. 100-200 mg/day bepridil successfully converted AF to SR in 58 % of the 
patients within 6 month (2.1 in average) and maintained that for 18 months in 81 % of these patients [377]. Similarly, 
53 % of the 60 patients with long-lasting persistent AF were converted to SR by bepridil (100-200 mg/day for 8 
weeks). Comparing these responders and non-responders revealed that the only difference was that the prolongation 
of fibrillation CL became significantly larger in responders suggesting that repetitive evaluation of fibrillation CL 
can be a feasible index to predict the efficacy of bepridil therapy [378]. Another study showed the same results 
(conversion in 50 % of the patients by 200 mg/day bepridil) and reached the same conclusion regarding responders 
[379]. When bepridil was compared to other antiarrhythmic drugs, some studies found bepridil to be superior for 
instance over amiodarone in patients with persistent AF as the conversion to SR was achieved in 35 % of patients 
with amiodarone (400 mg/day for 7 days followed by 200 mg/day) and in 85 % of bepridil receiving patients (150 
mg/day for 2 weeks followed by 100 or 200 mg/day according to the age, gender, body weight, renal function and 
QT interval of the patients). The time elapsed till conversion was significantly shorter with bepridil (2.3 months) 
compared to amiodarone (3.2 months). Moreover, bepridil was also more effective in maintaining SR after 
conversion (50 % of patients in the amiodarone group and 75 % of bepridil patients) [380]. Similarly, in patients with 
AF longer than 3 months, bepridil (200-600 mg/day for 3 weeks) seemed to be more effective in conversion of the 
AF to SR compared to amiodarone but unfortunately also more arrhythmogenic (VT, prolongation of QTc interval 
and TdP) than amiodarone with which no ventricular arrhythmias were seen [134]. Comparing bepridil to class IC 
drugs, their effectivity was similar (71 %) in the prevention of paroxysmal AF [381]. Bepridil (200 mg/day) proved 
to be more effective in reverting AF to SR alone or in combination with aprindine than electrical cardioversion [382]. 
Combination of bepridil with other antiarrhythmic drugs was studied as well. For instance, when 50-200 mg/day 
bepridil was added to a class I antiarrhythmic drug the frequency of symptomatic AF episodes was reduced to less 
than 10 % in 78 % of the patients and SR was restored within 3 months and maintained during the follow-up in 74 % 
of patients with persistent AF. During a mean follow-up period of 27±22 months, no potential complications 
occurred in any of the patients [383]. Again, combined therapy of bepridil (200 mg/day) and a class IC 
antiarrhythmic drug was more efficient for pharmacological cardioversion of refractory long-lasting persistent AF 
than bepridil alone [384]. Adding β-blocker (metoprolol or bisoprolol) to bepridil medication decreased the QTc 
interval (to a level which was still longer compared to that with bepridil alone) and significantly decreased both the 
QTc dispersion and TDR induced by bepridil [385]. 
As seen before, bepridil is more effective in atrial than in ventricular arrhythmias but sometimes arrhythmogenic 
effects were also reported as severe adverse effects. In a large trial involving 459 patients with AF or AFL, 4 % of 
the patients receiving 100-200 mg bepridil daily had adverse effects during an average follow-up of 20 months. 
Marked QT prolongation occurred in 13, bradycardia in 6 and dizziness and general fatigue in 1 patient each. TdP 
occurred in 4 of 13 patients usually triggered by hypokalemia and sudden decrease in HR. Therefore careful 
observation of serum potassium concentration and the ECG should always be done during bepridil administration, 
particularly in elderly patients [386]. A trial involving 90 patients demonstrated that bepridil dose-dependently 
reduced AF and converted it to SR. Unfortunately the AF reoccurrence was high (75 and 91 % with 200 and 100 
mg/day dose, respectively) and adverse effects (VT, QT prolongation, sinus bradycardia) were frequent 
(approximately 10 %) indicating that the balance between benefits and risks of the drug should be individualized 
[387]. In 284 paroxysmal or persistent AF patients, the clinical outcome did not improve with bepridil during a 
median follow-up of 17 month and the probability of progression to permanent AF was 23.5 % at 5 years. QTc 
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interval prolongation was observed when plasma concentrations of bepridil were higher than 800 ng/ml and TdP 
occurred in two patients without structural heart disease taking 200 mg daily [388]. 
 
AH-1058 
Animal studies with AH-1058 
AH-1058 exerted antiarrhythmic action in several species. For instance in the ouabain-induced arrhythmia 
model of the guinea-pig, pretreatment with AH-1058 (0.1-0.3 mg/kg, intravenously) delayed the appearance of VPC 
and VF in contrast to verapamil (1 mg/kg, intravenously) which failed to affect these arrhythmias [38]. In rat hearts 
subjected to 5-min coronary occlusion followed by 10-min reperfusion, AH-1058 (both at 0.1-0.3 mg/kg, 
intravenously and 2-4 mg/kg per os) inhibited the incidence of both VT and VF. In contrast, even in a higher dose (1 
mg/kg, intravenously) the aconitine-induced arrhythmias were not affected in rats [38]. AH-1058 (100 µg/kg, 
intravenously) effectively suppressed epinephrine-, digitalis- as well as two-stage coronary ligation-induced 
ventricular arrhythmias in dogs and exerted weak hypotensive effects. In contrast, verapamil suppressed only the 
epinephrine-induced ventricular arrhythmia and produced severe hypotension. These results indicate that AH-1058 
may possess a more selective inhibitory action on calcium channels in the heart than on those located in the vessels. 
The antiarrhythmic actions of either intravenously or orally administered AH-1058 did not correlate with drug 
plasma concentrations and were slower in onset and longer lasting than those of verapamil [389]. 
 
AP-792 
Animal studies with AP-792 
AP-792 (Fig. 5.) proved to possess antiarrhythmic properties using the epinephrine-, digitalis- and two-
stage coronary ligation-induced canine ventricular arrhythmia models as intravenous administration of AP-792 (0.3 
or 1.0 mg/kg) effectively suppressed each of the ventricular arrhythmias and its antiarrhythmic action was slow in 
onset and long-lasting [390]. 
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TABLE 6. Human studies describing the pro- and antiarrhythmic actions of other CCAs. 
 
DRUG / dose Proarrhythmic action Antiarrhythmic action Reference 
Mibefradil (RO 40-
5967) / 150 mg daily 
per os 
induced cardiac complications 
related to AV block and 
bradycardia  
 [193] 
Mibefradil / applied as 
co-medication 
caused TdP  [347] 
Bepridil / 200-600 
mg/day for 3 weeks 
in persistent AF patients VT, 
prolongation of QTc interval and 
TdP was observed 
 [134] 
Bepridil / 200-600 
mg/day for 3 weeks 
in patients with persistent AF, 
induced VT, prolongation of QTc 
interval and TdP more often 
compared to amiodarone  
 [134] 
Bepridil / 100-200 
mg/day  
induced QT prolongation, 
bradycardia, TdP usually triggered 
by hypokalemia, sudden decrease 
in HR in patients with AF or AFL 
 [386] 
Bepridil / plasma level 
of approximately 300 
ng/ml  
 suppressed AF [376] 
Bepridil / 100-200 
mg/day 
 successfully converted AF to SR in 
about half of the patients 
[377]  
[378] 
Bepridil / 150 mg/day 
for 2 weeks followed 
by 100 or 200 mg/day 
 converted AF to SR in shorter time 
and maintained SR for a longer period 
compared to amiodarone  
[380] 
Bepridil / applied as 
co-medication with 
various antiarrhythmic 
drugs 
 prevented paroxysmal AF, converted 
AF to SR in persistent AF 
[381] 
[382] 
[383] 
Bepridil / a single 
dose of 800 mg 
followed by 500-600 
mg 
 prevented VT initiation in non-
responding VT patients 
[369] 
Bepridil / 2 mg/kg 
intravenously 
 terminated AV reentrant tachycardia 
in a third of patients 
[232] 
Bepridil / 900 mg/day  prevented the induction of sustained 
VT in 50 % of patients 
[372] 
Bepridil / mean dose 
of 156 mg/day 
 suppressed ventricular 
tachyarrhythmias and decreased the 
frequency of ventricular 
tachyarrhythmia recurrences in 30 % 
of the patients  
[373] 
Bepridil / 200 mg/day  reduced the frequency of VF episodes 
in idiopathic VF  
[374] 
Bepridil / 900 mg for 
2 days followed by 
400 mg/day 
 moderate antiarrhythmic efficacy in 
patients with ventricular arrhythmias 
[375] 
 
10. Concluding remarks 
 
As was shown in this review, class IV agents, acting through several mechanisms, provide antiarrhythmic 
action against mainly supraventricular tachyarrhythmias. These drugs, especially the compounds of 
phenylalkylamine group, are unfortunately not entirely devoid of proarrhythmic side effects. These side effects could 
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probably be minimized with inhibition of other ion channels making these compounds to be able to target multiple 
sites. This clearly could be observed with BRL-32872 or AH-1058. Other compounds like monatepil (AJ-2615) can 
have a potentially useful side effect (lowering blood pressure) due to the blockade of alpha-1 adrenergic receptors. 
Nowadays the discovery of new pharmacological targets to treat cardiac arrhythmias is a rapidly growing area of 
research. Relatively new targets include for instance gap junction proteins or ion channels like IKAch, IKur, which 
chennels can not be found on the entire myocardium. But the successful application of amiodarone and bepridil in 
the antiarrhythmic therapy reminds us that a compound with multiple target sites is probably as good as, if not better, 
than a very selective ion channel blocker. 
Another conclusion based on this review can be that mother compounds like verapamil and diltiazem in the group of 
phenylalkylamines and benzothiazepines, respectively, are still very much used in the medical practice. This is the 
case regardless the existence of numerous newer derivatives. These newer compounds can actually be more selective 
to inhibit the L-type calcium channels but their other effects make them less likely to have an advantage over the 
mother compound. This highlights the long and cumbersome process of drug design. 
CCAs are still in use for antiarrhythmic therapy but their indication is very narrow. These drugs are not the first 
choice to be given in most cases but both verapamil and diltiazem are recommended for both acute and long-term 
rate control of AF as well as in AF associated with hyperthyroidism when beta-blocker is contraindicated. The 
application of these non-dihydropyridine compounds should also be considered in AF with pulmonary disease and 
acute coronary syndrome. 
 
LIST OF ABBREVIATIONS 
 
AF: atrial fibrillation 
AFL: atrial flutter 
AMI: acute myocardial infarction 
AP: action potential 
APA: action potential amplitude 
APD: action potential duration 
ATP: adenosine triphosphate 
AV: atrioventricular 
BKCa: large-conductance calcium-activated potassium channel 
BP: blood pressure 
CCA: calcium channel antagonist 
CF: coronary flow 
CL: cycle length 
CO: cardiac output 
CT: conduction time 
dP/dtmax: maximal rate of pressure rise 
EAD: early afterdepolarization 
EC50: half-effective concentration 
ERP: effective refractory period 
HEK: human embryonic kidney 
hERG: human ether-a-go-go 
HF: heart failure 
HR: heart rate 
IC50: half-inhibitory concentration 
ICa,L: L-type calcium current 
ICa,T: T-type calcium current 
IK1: inward rectifier potassium current 
IK,Ach: acetylcholine-activated potassium current 
IK,ATP: ATP dependent potassium current 
IK,Na: sodium activated potassium current 
IKr: rapid component of delayed rectifier potassium current 
IKs: slow component of delayed rectifier potassium current 
IKur: ultrarapid component of delayed rectifier potassium current 
INa: sodium current 
INCX: Na+/Ca2+ exchange current 
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Ito: transient outward potassium current 
LAD: left anterior descending coronary artery 
LQTS: long QT syndrome 
MAP: mean arterial pressure 
MDP: maximal diastolic potential 
PSVT: paroxysmal supraventricular tachycardia 
RBBB: right bundle branch block 
RMP: resting membrane potential 
RP: refractory period 
SA: sinoatrial 
SMC: smooth muscle cell 
SR: sinus rhythm 
SVT: supraventricular tachycardia 
TdP: torsade de pointes 
TDR: transmural dispersion of repolarization 
VEB: ventricular ectopic beat 
VF: ventricular fibrillation 
Vmax: maximal rate of depolarization 
VPC: ventricular premature complex 
VR: ventricular rate 
VT: ventricular tachycardia 
WPW: Wolff-Parkinson-White 
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